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Many of the most promising strategies for tissue engineering and regeneration aim to replicate 
natural cellular microenvironments including matrix components, growth factors, and cellular 
proteins as a means to guide the migration, proliferation, and differentiation of progenitor cells. 
Combinations of growth factors synergistically enhance tissue regeneration, but typically require 
sequential, rather than co-delivery from biomaterials for maximum efficacy. Polyelectrolyte 
multilayer (PEM) coatings can deliver multiple factors without loss of activity; however, 
sequential delivery has been limited due to interlayer diffusion of multiple factors that results in 
co-delivery.  
This dissertation examined the incorporation of a biomimetic calcium phosphate (bCaP) 
layer into a poly-L-Lysine/poly-L-Glutamic acid PEM film (bCaP-PEM) to provide sequential 
delivery of two different factors. The bCaP-PEM was uniformly deposited onto two-dimensional 
(2-D), and three-dimensional (3-D) porous substrates. Measurements of MC3T3-E1 
osteoprogenitor cell proliferation and viability over time were used to evaluate kinetics of active 
biomolecule delivery and demonstrate that bCaP-PEM enables sequential delivery of a 
proliferative factor (fibroblast growth factor -2 (FGF-2) followed by a cytotoxic factor 
(antimycin A, AntiA) a few days later. Alterations to the PEM composition via increasing the 
number of bilayers or using the D- enantiomer polyelectrolytes hindered delivery of the 
proliferative factor. Increasing the bCaP layer thickness resulted in sustained delivery of the 
embedded factor as compared to burst delivery. Accelerated cell-mediated delivery kinetics from 
the bCaP-PEM coating was demonstrated in vitro using a murine macrophage cell line. Scanning 
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electron microscopy revealed the bCaP-PEM coating could be uniformly applied to the 3-D, 
commercially available bone graft substitute Healos®, (DePuy Synthes Spine, Raynham, MA). 
Effects of sequential delivery of FGF-2, then bone morphogenetic protein 2 (BMP-2), from a 
bCaP-PEM coated Healos® scaffold was evaluated in vivo in a mouse calvarial defect model. 
This work resulted in the development of a novel, biomimetic coating capable of sequential 
delivery of two factors. This technology has potential to be applied in multiple research 
applications where a sequential delivery profile activated by cell degradation of the biomaterial 
is desired. 
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List of Figures 
Figure 2.1 Schematic representation of interlayer diffusion of Factors 1 and 2 in a PEM only 
coating (A), compared to prevention of interlayer diffusion of Factors 1 and 2 with the addition 
of bCaP to the PEM coating (B). The theoretical co- and sequential delivery profiles from a PEM 
only coating (C) and a bCaP-PEM coating (D) respectively. 
Figure 2.2 Sandblasted disk coating procedure for diffusion studies.  Step 1: Factor 2 (AntiA) is 
adsorbed. Step 2A: disks are submerged in Solution A to deposit a thin layer of amorphous 
calcium phosphate (CaP). Step 2B: disks are submerged in Solution B to deposit nanocrystalline 
calcium phosphate, (bCaP). Step 3: 8-30 bilayers of PEM are applied by automated dip 
procedure. Step 4: Factor 1 (FGF-2) is adsorbed. 
Figure 2.3 Scanning electron microscopy images of the surface morphology and cross-section of 
a sandblasted disk (A), and the sandblasted disks coated with: amorphous calcium phosphate 
CaP (B), nanocrystalline calcium phosphate bCaP (C), nanocrystalline calcium phosphate and 30 
bilayers of PEM (D), and 30 bilayers of PEM (E). B and E coating thickness was not measurable 
via SEM.  bCaP thickness = 5.8 + 1.8 μm (C). bCaP-PEM30 thickness = 16.3 + 2.2 μm (D). 
Figure 2.4 EDS analysis of the bCaP deposited on the TCPsb before (A) and after PEM30 
adsorption (B), revealed Ca/P atomic ratios of 1.95 + 0.12 and 1.52 + 0.50 respectively, not 
statistically different from the hydroxyapatite powder (1.71 + 0.04) nor each other. The 
composition of the bCaP coating was identified as poorly crystalline/nanocrystalline 
hydroxyapatite by XRD (C).  After PEM adsorption the bCaP became less crystalline (D).  
Figure 2.5 AntiA dose response curve.  The adsorbed AntiA IC50 was found to be 3.08 mM 
(black arrow).  The dose of AntiA selected to use for all studies was 40 mM (red arrow).   
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 ix 
Figure 2.6 Percent LIVE® stained area of MC3T3-Es cultured for 1 day on sandblasted disks 
coated with normal AntiA (TCPsb-AntiA), AntiA after “PEM” processing, AntiA after “bCaP” 
processing, and no AntiA (TCPsb). AntiA = 213 μg/disk. (**** p < 0.0001). 
Figure 2.7 Day 1 percent cell death of MC3T3-E1s cultured on TCPsb coated with AntiA, 
AntiA embedded under PEM8, and AntiA embedded under CaP-PEM8 relative to their AntiA-
free controls (A). Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with 
CaP-PEM8 (blue) and AntiA embedded under CaP-PEM8 (red) for days 1, 3, and 5 (B). AntiA = 
213 μg/disk. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
Figure 2.8 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with CaP-
PEM30 (blue) and Anti embedded under CaP-PEM30 (red) for days 1, 3, 5, and 7. AntiA = 213 
μg/disk. (* p < 0.05, ** p < 0.01). 
Figure 2.9 Day 1 % LIVE® stained area of MC3T3-E1s cultured on AntiA with no coating 
compared to its AntiA-free control, AntiA embedded under PEM30 compared to its AntiA-free 
control, and AntiA embedded under bCaP-PEM30 compared to its AntiA-free control (A), (**** 
p value < 0.0001). The calculated day 1 % cell deaths of AntiA, AntiA-PEM30, and AntiA-
bCaP-PEM30 relative to their AntiA-free controls (B), (* p value < 0.05, *** p value < 0.001, 
**** p value < 0.0001). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on 
TCPsb (C) vs. TCPsb coated with AntiA (D), PEM30 (E) vs. AntiA-PEM30 (F), and bCaP-
PEM30 (G) vs. AntiA-bCaP-PEM30 (H). Scale bar = 250 μm. 
Figure 2.10 MC3T3-E1 FGF-2 dose response day 1 LIVE® staining. (* p < 0.05, ** p < 0.01, 
**** p < 0.0001). The 150 ng FGF-2 dose was selected to use for all studies. 
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 x 
Figure 2.11 Schematic representation of Factor 1 (A) and Factor 2 (B) location within the bCaP-
PEM30 coating. The theoretical immediate, and delayed delivery profiles of Factor 1 (C) and 
Factor 2 (D) respectively. 
Figure 2.12 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30-FGF2 (blue) and 
bCaP-PEM30 (green) for up to 5 days (A), (** p < 0.01, *** p < 0.001, **** p < 0.0001) (FGF-
2 = 150 ng/disk). Fluorescent images of day 1 LIVE® staining of MC3T3-E1s cultured on 
TCPsb coated with bCaP-PEM30-FGF2 (B) and bCaP-PEM30 (C). Scale bar = 250 μm.  
Figure 2.13 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with bCaP-
PEM30 (green, -A/-F) and bCaP-PEM30-FGF2 (blue, -A/+F) at 4h (A), and day 1 (B), (** p < 
0.01).  Fluorescent images of LIVE® staining of MC3T3-E1s cultured on TCPsb coated with 
bCaP-PEM30 and bCaP-PEM30-FGF2 after 4 h (C, D) and 1 day (E, F). 
Figure 2.14 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30 (green) and AntiA-
bCaP-PEM30 (red) for up to 5 days (A), (* p < 0.05, ** p < 0.01, *** p < 0.001) (AntiA = 213 
μg/disk). Fluorescent images of day 3 LIVE® staining of MC3T3-E1s cultured on TCPsb coated 
with bCaP-PEM30 (B) and AntiA-bCaP-PEM30 (C). Scale bar = 250 μm.  
Figure 2.15 Percent LIVE® staining of MC3T3-E1s cultured in day 1- or day 3-release medium 
collected from bCaP-PEM30-FGF-2 (-A/+F, blue) or AntiA-bCaP-PEM30-FGF-2 (+A/+F, 
ornage) coated disks incubated at 37°C without cells, (FGF-2 = 150 ng/disk, AntiA = 213 
μg/disk). 
Figure 2.16 Day 1 LIVE® stained area of MC3T3-E1s cultured on the FGF-2 groups (+F) 
compared to their FGF-2-free controls (-F) (FGF-2 = 150 ng/disk) (A), (*** p < 0.001, **** p < 
0.0001). Percent LIVE® stained area of MC3T3-E1 cells cultured on bCaP-PEM30-FGF2 (blue) 
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 xi 
and AntiA-bCaP-PEM30-FGF2 (orange) over time (B), (**** p < 0.0001). Fluorescent images 
of LIVE® staining of MC3T3-E1s cultured on bCaP-PEM30-FGF-2 (-A/+F), and AntiA-bCaP-
PEM30-FGF-2 (+A/+F), at time points 4 h, days 1-5 (C). Scale bar = 250 μm. 
Figure 2.17 Schematic representation of “in and out” diffusion and exponential growth of 
hydrophilic polyelectrolytes during layer-by-layer build up of the PEM film (A). Resulting 
interlayer diffusion of multiple factors within the PEM layers (B) and theoretical co-delivery of 
factors (C).  
Figure 3.1 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2 
(orange checker) as compared to cells cultured on bCaP-PEM102-FGF2 (blue checker) on days 
1, 3, and 5 (A), (* p < 0.05). Percent LIVE® stained area of MC3T3-E1s cultured on the control 
bCaP-PEM30-FGF2 as compared to cells on bCaP-PEM102-FGF2, (B), (*** p < 0.001). 
Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 
as compared to cells on AntiA-bCaP-PEM102-FGF2, (C), (* p < 0.05, ** p < 0.01). AntiA = 
213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.2 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2 
(orange stripes) as compared to cells cultured on bCaP-PEMD30-FGF2 (blue stripes) on days 1, 
3, and 5 (A), (**** p < 0.0001). Percent LIVE® stained area of MC3T3-E1s cultured on the 
control bCaP-PEM30-FGF2 as compared to cells on bCaP-PEMD30-FGF2, (B), (* p < 0.05, ** 
p < 0.01). Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-
PEM30-FGF2 as compared to AntiA-bCaP-PEMD30-FGF2, (C), (* p < 0.05). AntiA = 213 
μg/disk, FGF-2 = 150 ng/disk. 
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Figure 3.3 Schematic representations of bCaP-PEM30 coatings made with bCaP prepared by 7 h 
in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B (C). 
Figure 3.4 Scanning electron microscopy images of the surface morphology and cross-section of 
bCaP prepared by 7 h in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B 
(C). bCaP(7) thickness = 1.8 + 0.7 μm, bCaP(24) thickness = 5.8 + 1.8 μm, and bCaP(48) 
thickness = 24.0 + 2.4 μm.  
Figure 3.5 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP(7)-PEM30-
FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 on time points 4 h, 
days 1-4 (A), (** p < 0.01). Fluorescent images of MC3T3-E1s cultured on AntiA-bCaP(7)-
PEM30-FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 (B). AntiA 
= 213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.6 Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(24)-PEM30-FGF2 (-
A/+F) and AntiA-bCaP(24)-PEM30-FGF2 (+A/+F) (A) with corresponding fluorescent images 
of cells (B), (**** p < 0.0001). (Note, this data is from Fig. 3.3 and is being shown for 
reference). Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(48)-PEM30-FGF2 (-
A/+F) and AntiA-bCaP(48)-PEM30-FGF2 (+A/+F) (C) with corresponding fluorescent images 
of cells (D), (* p < 0.05, ** p < 0.01*** p < 0.001, **** p < 0.0001). (Note, data obtain for 
Days 5, 6 and 7 were obtained from a separate experiment). Scale bar = 250 μm. AntiA = 213 
μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.7 Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24h)-PEM30 
demonstrating burst delivery of AntiA (A) and bCaP(48h)-PEM30 demonstrating sustained 
delivery of AntiA (B).  
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Figure 3.8 Percent LIVE® stained area of RAW 264.7 s cultured on bCaP-PEM30-FGF2 (-
A/+F) (A), and AntiA-bCaP-PEM30-FGF2 (+A/+F) (B) at seeding densities of 7.9k or 30k 
cells/cm2 (* p < 0.05, ** p < 0.01).  Fluorescent images of the cells at 4 h of culture (C). Scale 
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.9 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (-
A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 7.9k cells/cm2 (A), (* p < 0.05).  
Fluorescent images of the cells at 4 h, 1 day, 2 days and 3 days of culture (B). Scale bar = 250 
μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.10 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (-
A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 30k cells/cm2 (A), (* p < 0.05, ** p < 
0.01, *** p < 0.001).  Fluorescent images of the cells at 4 h, 1, 2, and 3 days of culture (B). Scale 
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.11 Percent LIVE® stained area of RAW 264.7 cells seeded at 30k cells/cm2 on bCaP-
PEM30 (green, -A/+F), bCaP-PEM30-FGF2 (blue, -A/+F), AntiA-bCaP-PEM30 (red, +A/-F), 
and AntiA-bCaP-PEM30-FGF2 (orange, +A/+F) at 4 h of culture, (A). Percent LIVE® stained 
area of RAW 264.7s seeded at 30k cells/cm2 on AntiA-bCaP-PEM30 (red), and AntiA-bCaP-
PEM30-FGF2 (orange) at 4 h, and days 1-3, (B). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001). AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.  
Figure 3.12 The theoretical sequential delivery profile of FGF-2 and AntiA from bCaP-PEM30 
cultured with osteoprogenitor cells (MC3T3-E1s at 40k cell/cm2) (A), as compared to the co-
delivery of factors from bCaP-PEM30 cultured with macrophages (RAW 264.7a at 30k 
cells/cm2) (B).  
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Figure 4.1 Schematic representation of BMP-2 only (A), and BMP-2 and FGF-2 (B) delivery 
from Healos-bCaP-PEM. The theoretical single- (C), and sequential- (D) delivery profiles from 
Healos-bCaP-PEM.  
Figure 4.2 Schematic representation of the Healos-BMP2-CaP-PEM8-FGF2 procedure made 
with only amorphous calcium phosphate (CaP) with no mixing, and 8 bilayers of PEM. 
Figure 4.3 Schematic representation of the Healos-BMP2-bCaP-PEM30-FGF2 procedure made 
with biomimetic, nanocrystalline, calcium phosphate (bCaP) with mixing, and 30 bilayers of 
PEM.  
Figure 4.4 Low magnification SEM images of Healos® (A) and Healos® coated with 
amorphous CaP (B), (scale bar = 50 μm). High magnification SEM image of Healos® coated 
with amorphous CaP (C), (scale bar = 10 μm). 
Figure 4.5 SEM images of Healos® (A), Healos® coated with nanocrystallline bCaP(7) made 
by 7 h in Solution B (B), and nanocrystalline bCaP(24) made by 24 h in Solution B (C), (scale 
bar = 500 μm).  
Figure 4.6 Low magnification SEM images of the outer and inner fibers of Healos® (A) and 
Healos® coated with nanocrystalline bCaP(7) (B), (scale bar = 10 μm). High magnification SEM 
image of the outer and inner fibers of Healos® coated with nanocrystalline bCaP(7) (C), (scale 
bar = 1 μm). 
Figure 4.7 SEM images of the outer (A) and inner fibers (B) of Healos® coated with 
nanocrystalline bCaP(7) and 30 bilayers of PEM. 
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Figure 4.8 4-week post-surgery x-rays (A, B), microCT 3-D reconstructions (C, D), and 
microCT cross-sections (E, F) of calvaria implanted with Healos® coated with CaP-PEM8 (top 
panel) and BMP2-CaP-PEM8 (bottom panel).  BMP-2 dose = 0.5 μg. New bone formation is 
circled in red. 
Figure 4.9 Schematic representation of where within the defect FGF-2 effects are being 
observed and quantified 1-week post-surgery (A). Fluorescent images of DAPI and EdU stained 
cells showing increase in staining with the addition of 25 and 125 ng FGF-2 as compared to 
BMP-2 alone (B). Quantified results showing 125 ng FGF-2 dose significantly increases number 
of EdU+ cells on day 7 as compared to BMP-2 alone and 25 ng FGF-2 dose (C). (* p < 0.05, ** 
p < 0.01). (Healos® was coated with BMP2-CaP-PEM8 + FGF2).   
Figure 4.10 4-week post-surgery microCT 3-D reconstructions (A, B), and microCT cross-
sections (C, D), of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (top panel) 
and BMP2-CaP-PEM8-FGF2 (bottom panel).  BMP-2 dose = 0.5 μg, FGF-2 dose = 125 ng. New 
bone formation is circled in red and quantified in (E). 
Figure 4.11 4-week post-surgery microCT 3-D reconstructions (top panel) and microCT cross-
sections (bottom panel) of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (A), 
and BMP2-CaP-PEM8-FGF2 with an FGF-2 dose = 0.25 ng (B), 5 ng (C), and 100 ng (D).  
BMP-2 dose = 0.5 μg. New bone formation is circled in red and quantified in (E). (* p < 0.05, ** 
p < 0.01). 
Figure 4.12 3-week post-surgery microCT 3-D reconstructions (top panel) and microCT cross-
sections (bottom panel) of calvaria implanted with Healos® coated with bCaP(7)-PEM30 (A), 
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BMP2-bCaP(7)-PEM8 (B), and BMP2-bCaP(7)-PEM8-FGF2 (C). BMP-2 dose = 2 μg, FGF-2 
dose = 5 ng. New bone formation is circled in red and quantified in (D).  
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List of Abbreviations  
-A/-F no AntiA, no FGF-2 
-A/+F no AntiA, FGF-2 
+A/-F AntiA, no FGF-2 
+A/+F AntiA and FGF-2 
AntiA antimycin A 
bCaP nanocrystalline calcium phosphate made with 24 h in Solution A 
bCaP(24) nanocrystalline calcium phosphate made with 24 h in Solution A 
bCaP(48) nanocrystalline calcium phosphate made with 48 h in Solution A 
bCaP(7) nanocrystalline calcium phosphate made with 7 h in Solution A 
BMP-2 bone morphogenetic protein-2 
BMP-5 bone morphogenetic protein-5 
BMP-6 bone morphogenetic protein-6 
BMP-7 bone morphogenetic protein-7 
CaP amorphous calcium phosphate 
DAPI 2-(4-amidinophenyl)-1H -indole-6-carboxamidine 
DS dextran sulfate 
ECM extra cellular matrix 
EDS energy dispersive x-ray spectroscopy 
EdU 5-ethynyl-2'-deoxyuridine 
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Chapter 1 
Introduction and Specific Aims 
1.1 Introduction 
We have entered an era of regenerative medicine resulting in new biomimetic coatings and 
implantable devices focused on not just repairing the injured or diseased tissue, but on 
stimulating the body’s natural tissue regeneration. As a result, new multi-component biomaterial 
drug delivery systems are being developed to initiate multiple, critical aspects of the natural 
biological tissue regeneration process, including: infection control [1], as well as recruitment and 
migration [2], and proliferation and differentiation [3] of progenitor cells. These processes are 
generally governed by the timely release and exposure to multiple growth factors [4, 5]. 
Therefore rather than being limited to the delivery of a single growth factor, biomaterial systems 
are needed to control the release of multiple therapeutic agents at optimized physiological doses, 
ideally with specific spatiotemporal patterns [6]. This dissertation is focused on the development 
of a novel, biomimetic, multifactor, sequential delivery system capable of being applied to two-
dimensional or three-dimensional substrates; in addition, the delivery system is used to 
investigate the potential biological benefit of sequential delivery of growth factors to stimulate in 
vivo osteogenesis. 
1.1.1 Growth Factors Used in Clinical Trials and Commercial Products 
There are a number of growth factors already being clinically investigated to stimulate natural 
tissue regeneration.  These include vascular endothelial growth factor (VEGF, clinical trials) [7-
15], fibroblast growth factor-2 (FGF-2, clinical trials) [15-18], bone morphogenetic protein-2 
(BMP-2, INFUSE Bone Graft, Medtronic, FDA approved) [19, 20], bone morphogenetic protein-
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7 (BMP-7, OP-1 Putty, Stryker, FDA approved) [21, 22], and platelet-derived growth factor 
(PDGF-BB, GEM 21S, Osteohealth, FDA approved) [23, 24]. VEGF and FGF-2 have been 
primarily focused on the treatment of cardiovascular diseases, while BMP-2 and BMP-7 have 
been focused on bone fracture and defect repair, and PDGF-BB was created to enhance 
periodontal regeneration. To date, no clinical trials in the USA have been conducted on the use 
of FGF-2 on bone fracture repair, however clinical trials in Japan have shown that local 
administration of FGF-2 accelerates healing of tibial shaft fractures [25], and stimulates 
periodontal regeneration [26].    
The successful use of growth factors clinically has been very limited. For example, when 
administered intravenously, VEGF has a half-life of only 30 min [13], resulting in the need for 
excessive dosing and injections [14, 15].  Excessive VEGF should be avoided because it can lead 
to pathological vessel formation at non-target sites [27]. BMP-2 delivered via a collagen sponge 
(INFUSE Bone Graft, Medtronic, FDA approved) significantly enhances bone formation and 
successful spinal fusion [28]; however its use has been limited due to complications with the 
required high dose of BMP-2 necessary for adequate bone formation. It only takes nanogram 
quantities of BMP-2 per gram bone matrix to trigger the bone repair cascade, however 
microgram quantities of BMP-2 per gram of the matrix material are required to produce adequate 
bone formation [4, 29].  These complications include severe inflammation, ectopic bone 
formation, osteolysis, seroma formation, and possible increase in the risk of malignancy, [19, 
30].  These problems stem from the collagen sponge’s inability to contain the supraphysiologic 
dose of BMP-2 in the local tissue environment. 
Healos® is a commercially available bone graft substitute made of type I collagen fibers 
with a hydroxyapatite coating (DePuy Synthes Spine, Raynham, MA).  Healos® has been 
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investigated for the delivery of human growth/differentiation factor-5 (GDF-5) [31, 32], and 
BMP-2 [33] to aide in bone regeneration.  Again the success of these approaches has been 
limited. Gohil et al. discovered that delivery of BMP-2 from Healos® was not confined to the 
site of BMP-2 implantation and significant bone formation was observed in the neighboring 
defect site [33]. 
It is postulated that the reason the clinical use of growth factors and their combination 
with commercial scaffolding materials have unwanted side effects is because the delivery 
approaches employed lack any control over release.  These factors were intravenously 
administered [14-16] or were adsorbed as a bolus dose of growth factor to a scaffolding material 
[19-22]; because these methods lack controlled release, supraphysiologic, excessive, doses need 
to be used to obtain the desired therapeutic effect. This is because a significant portion of the 
administered growth factor will diffuse away from the implantation site and be degraded via 
denaturation, oxidation or proteolysis [34, 35]. If the growth factor manages to remain active, the 
diffusion can lead to off-target, unwanted side effects [19, 27, 30, 33].  These unfavorable 
outcomes emphasize the need to develop a way to not only reduce the concentration of growth 
factor necessary to obtain a therapeutic effect, but to also develop biomaterials capable of 
controlling the release and delivery of these growth factors. 
1.1.2 Biology of Bone Repair  
Bone repair and regeneration involves the combination of cells, bioactive factors and 
extracellular matrix to stimulate the proliferation, differentiation and migration of 
osteoprogenitor cells [5, 36, 37]. Fracture healing can occur in two ways, primary (direct) 
fracture healing, or secondary (indirect) fracture healing. Primary fracture healing requires rigid 
fixation and leads to the regeneration of bone structure without remodeling steps. The majority 
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of bones heal through secondary (indirect) fracture healing which consists of both endochondral 
and intramembranous bone healing [38]. Secondary fracture healing involves the following 
stages: hematoma formation, inflammation, callus formation, revascularization, mineralization 
and resorption of the callus, and bone remodeling [39]. After fracture, the hematoma will form 
within hours and begin the acute inflammatory stage that typically lasts around 3 days.  This step 
is critical to bone healing because the hematoma initiates the signaling cascade that leads to 
successful bone formation [39, 40].  Inflammatory cells, including monocytes, will migrate into 
the extra cellular matrix (ECM) of the hematoma from the ruptured blood vessels and bone 
marrow cavity.  Mesenchymal stem cells (MSCs) will be recruited to the fracture site when cells 
within the hematoma release signaling molecules such as interleukin 6 (IL6), tumor necrosis 
factor alpha (TNFα), granulocyte colony-stimulating factor (GCSF), stromal cell-derived factor-
1 (SDF 1), and macrophage colony-stimulating factor (MCSF) [41]. The source of MSCs is an 
area of active investigation, however it is believed that they derive from the bone marrow and 
periosteum, and possibly bone lining cells [42]. 
During the first few days of fracture healing granulation tissue is formed within the defect 
where cartilaginous tissue will then form (soft callus) around days 7-10 and serve to aid in 
fracture stabilization [43] (endochondral ossification); simultaneously, an intramembranous 
ossification response occurs at the proximal and distal ends of the fracture adjacent to the 
periosteum, generating a hard callus [38]. During this time chondrocytes will undergo 
hypertrophy and the cartilaginous callus will calcify. Concurrently, blood vessels will penetrate 
the chondrogenic tissue, bringing with them mesenchymal progenitors that initiate cartilage 
replacement with woven bone [38].  During this time, collagen type I and II matrix production 
increases, and expression of members of the transforming growth factor-β superfamily (TGF-β2, 
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-β3, GDF-5, BMP-2, -5, and -6) which are involved in cell proliferation and differentiation, will 
elevate [44, 45]. Vascular endothelial growth factor (VEGF), known to be highly expressed in 
hypertrophic chondrocytes, is considered a key regulator in the transformation of the 
cartilaginous matrix into vascularized osseous tissue [46].  The osseous matrix, or hard callus, 
will then gradually be replaced with woven bone via osteoclast resorption of the hard callus.  
This stage of fracture repair is associated with expression of collagen type I, osteocalcin, and 
alkaline phosphatase [47], and relies on key regulators of bone homeostasis such as receptor 
activator of nuclear factor kappa-β ligand (RANKL), receptor activator of nuclear factor kappa-β 
(RANK) and osteoprotegerin (OPG) [48, 49]. During the remodeling phase, woven bone will be 
resorbed by osteoclasts and replaced by lamellar bone via osteoblasts, leading to the mechanical 
and biological restoration of bone function [38]. 
In the present studies, a critical-sized calvarial defect mouse model was selected for the 
in vivo experiments, which also heals through secondary (indirect) bone formation. Contrary to 
callus formation and subsequent endochondral ossification, which is the main mechanism of 
secondary (in direct) fracture healing described previously, calvarial defects repair and 
regenerate in a slightly different way with their main mechanism of bone healing being 
intramembranous ossification.  Intramembranous ossification is a more direct method of bone 
formation that skips the cartilaginous steps associated with endochondral ossification. During 
intramembranous ossification, inflammatory cells and MSCs will first be recruited to the defect 
site. The MSCs will replicate and condense into compact nodules committing themselves as 
osteoprogenitor cells.  These cells will differentiate into osteoblasts and secrete a collagen-
proteoglycan matrix that is able to bind calcium salts [50], and are associated with the expression 
of type 1 collagen, bone sialoprotein and osteocalcin [51]. Through this binding, the matrix 
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becomes calcified with the enzyme alkaline phosphatase playing a key role [52].  As 
calcification proceeds bony spicules will radiate out from the region where ossification began.  
During this process some osteoblasts will become trapped within the bony pockets and will then 
differentiate into osteocytes or mature bone cells [52].  Over time, the defect will be filled with 
spongy bone that will continually be remodeled through the combined action of osteoblasts and 
osteoclasts.  At this point new bone formation is slowed and the compact MSCs surrounding the 
area of new bone formation will form the periosteum [50].  The mechanism of intramembranous 
ossification is primarily controlled through fibroblast growth factors (FGFs), with FGF-2 and 
FGF-18 being considered most important for calvarial regeneration [51], bone morphogenetic 
proteins (BMPs), and the transcriptional factor core-binding factor alpha (1) (Cbfa1). Cbfa1 is 
considered to play a critical role during BMP-induced osteoblastic differentiation [53]. In 
addition it has been shown that BMPs act in concert with FGFs to control calvarial growth, 
development, and regeneration [54] and will be further discussed in the following section. 
Considering the important roles of osteoprogenitors and osteoblasts on bone regeneration, 
a mouse osteoprogenitor/pre-osteoblast cell line, MC3T3-E1s, was selected for our in vitro 
assays to screen the effectiveness of the biomaterial to provide sequential, multifactor, cell-
mediated delivery. In addition to the osteoprogenitors, monocytes and osteoclasts are two other 
cell types that play a vital role in bone regeneration and fracture healing.  As new bone matrix is 
deposited by osteoblasts on the outer surface of new bone, subsequent resorption of bone matrix 
on the inner surface is accomplished via osteoclasts.  Osteoclasts are multinucleated cells that are 
derived from the same precursors as monocytes.  These monocytes enter the healing defect site 
through the blood vessels and will differentiate into osteoclasts in the presence of RANKL, 
which is secreted by the osteoprogenitor cells already present in the defect [55].  The osteoclasts 
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are capable of dissolving both the inorganic and the protein portions of the bone matrix.  They 
accomplish this by extending their cellular processes into the matrix and pumping out hydrogen 
ions into the surrounding material, thereby producing an acidic environment that can dissociate 
the mineralized matrix [50].  The combined action of osteoblasts and osteoclasts must be tightly 
regulated for bone fracture healing and normal bone maintenance, therefore the cells and their 
precursors can act on each other. In addition to secreting RANKL and colony-stimulating 
factor both promoting osteoclast differentiation [56], osteoprogenitors can also secrete 
osteoprotegerin, deterring the differentiation of osteoclasts [55]. FGF-2 (provided from 
macrophages, MSCs and osteoblasts [36]) can increase the formation of osteoclast-like cells [57] 
and activate mature osteoclasts [58].  The actions and effects of all of these cell types are 
important to consider when developing a biomaterial to enhance bone regeneration, therefore a 
mouse monocyte cell line, RAW 264.7s, was selected to also screen the effectiveness of the 
biomaterial to provide sequential, multifactor, cell-mediated delivery in vitro. 
1.1.3 Growth Factors Involved in Bone Repair and Regeneration 
One focus of the research conducted in this dissertation was to use a biomaterial to 
deliver multiple growth factors to stimulate the production of osteoblasts to produce new 
mineralized bone tissue. This involves first the recruitment to, and commitment of mesenchymal 
stem cells to the osteoblast lineage making them osteoprogenitors, followed by the proliferation 
of the osteoprogenitors, and then differentiation of the osteoprogenitors into functioning 
osteoblasts [59]. There are a number of growth factors involved in bone regeneration, but the 
major factor families involved with proliferation and differentiation of osteoprogenitors are 
fibroblast growth factors, transforming growth factor-βs, and bone morphogenetic proteins [36]. 
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Bone morphogenetic proteins (BMPs) are the main growth factors responsible for the 
differentiation of osteoprogenitor cells into functioning osteoblasts [36]. BMP-2, -4, and -7 have 
all been investigated for bone regeneration, however, it has been suggested that BMP-2 may be 
more osteoinductive compared to other BMPs [60].  BMP-2’s use clinically was the result of its 
extensive investigation in vivo in a variety of animal models; BMP-2 has been shown to 
stimulate bone regeneration in rats [61-63], rabbits [64, 65], dogs [66, 67], sheep [68, 69], and 
monkeys [65].  Because of its proven effectiveness at regenerating bone in vivo, and it use 
clinically, BMP-2 was selected as one of the growth factors to be delivered in the present studies.  
 There are twenty-two members to the fibroblast growth factor family [36], however 
fibroblast growth factor-2 (FGF-2) has been studied most for use in bone fracture healing.  This 
is because FGF-2 is known stimulator of osteoprogenitor proliferation [70] and plays an 
important role in maintaining bone mass [71].  FGF-2 has been shown to accelerate fracture 
healing via increasing callus size, mineral content, and mechanical strength of the healing defect 
site [72-75].  The Fgf2 gene is expressed during all stages of the fracture repair process [76], and 
its receptor (Fgfr2) is specifically expressed at sites of intramembranous ossification in 
differentiating osteoblasts [77]. Besides its clear involvement in bone fracture healing, FGF-2 
was selected for use in the present studies because of its synergistic effects when used with 
BMP-2. FGF-2 has been demonstrated to increase the BMP-2 sensitivity of osteoprogenitor cells 
[78, 79] via up-regulating BMP-2 levels and BMP-2 receptor expression [80, 81]. Recently, low 
concentrations of BMP-2 were shown to enhance calvarial defect repair in mice overexpressing 
FGF-2 in osteoprogenitor cells [82], suggesting FGF-2 can augment BMP-2-induced bone repair 
[83].  These findings lead to the hypothesis that the combined use of FGF-2 and BMP-2 could 
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decrease the supraphysiologic dose of BMP-2 necessary to stimulate bone formation, thereby 
decreasing the unwanted, off-target side effects that are associated with BMP-2’s clinical use. 
1.1.4 Optimizing FGF-2 and BMP-2 for Bone Healing 
There have been several studies investigating the combined use of FGF-2 and BMP-2 on in vitro 
and in vivo osteogenesis [84-101].  At first glance, the results of these studies have been 
somewhat contradictory.  For the most part, the combined use of FGF-2 and BMP-2 has been 
reported as stimulatory and synergistic.  However there are many examples where their 
combined use has been reported as inhibitory on osteogenesis [84, 86, 93, 95, 96, 100, 102].  
There are many factors to consider when combining growth factors.  For example, Charles et al. 
observed that the co-delivery of FGF-2 and BMP-2 in a mouse calvarial defect model was not 
stimulatory on in vivo osteogenesis over BMP-2 alone in young adult mice; however, the co-
delivery of both factors did in fact aid in new bone formation when tested in old mice [84]. There 
have also been examples where the combined use of FGF-2 and BMP-2 resulted in both 
stimulatory and inhibitory results [86, 93, 96].  In these studies it was found when combining 
high doses of FGF-2 (μg quantities) with BMP-2 it was inhibitory, where as low doses of FGF-2 
(ng quantities) with BMP-2 tended to be stimulatory.  The relative dosing of BMP-2 to FGF-2 
also seems to be important.  Wang et al. reported that ratios 8:1, 4:1, and 2:1 (BMP-2: FGF-2) 
were all stimulatory for in vitro and in vivo osteogenesis, however 2:1 produced the best 
outcomes [103]. For the examples where both stimulatory and inhibitory results were reported, 
ratios of 5:1 to 500:1 stimulated osteogenesis, where ratios of 1:1 and 1:25 were inhibitory [86, 
93, 96], suggesting the FGF-2 dose should be low compared to the BMP-2. 
 Besides dosing and taking into account the osteogenic potential of the model/cells being 
used (young vs. old), sequence of delivery is crucial to the success of the combined use of FGF-2 
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and BMP-2.  The best chance of success when using multiple growth factors is to mimic the 
natural tissue regeneration process. Growth factors have different effects on tissue regeneration 
depending on the developmental stage of the healing process they are present during.  As 
previously mentioned FGF-2 has proliferative effects on osteoprogenitors (early), and BMP-2 is 
the key factor involved in osteoprogenitor differentiation (late).  All of the inhibitory examples 
previously mentioned were co-delivery [86, 93, 95, 96, 100, 102]. In vitro studies have 
demonstrated that spiking first FGF-2 in cell culture medium, and then BMP-2 can increase 
osteogenesis over co-delivery of both factors and/or single factor delivery [85, 88, 90, 91]. BMP-
2 delivered too early, or before FGF-2 has been shown to be inhibitory [89, 104].  These results 
stress the need for new biomaterials to biomimetically deliver multiple growth factors in a 
sequential manner to maximize their stimulatory effects. 
1.1.5 Material Approaches for Growth Factor Delivery for Bone Regeneration 
A successful growth factor delivery biomaterial will maintain therapeutic concentrations of 
growth factor at the application site in a spatiotemporal pattern that mimics natural bone 
regeneration. There are two main approaches for the delivery of growth factors from 
biomaterials: 1) physical encapsulation of the growth factors in the delivery system, and 2) 
chemical immobilization of the growth factors to the matrix/substrate.  Physical encapsulation 
relies on both the diffusion of the growth factor out of the material and degradation rate of the 
material; chemical immobilization relies on chemical binding or affinity interactions between the 
growth factor and the substrate [4, 5, 27]. There are pros and cons to each approach. 
 Chemical immobilization incorporates a variety of techniques to conjugate growth factors 
directly to a scaffold or biomaterial. The simplest approach to delivering growth factors for bone 
regeneration involves the adsorption of growth factors directly to a scaffold through non-
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covalent binding (surface adsorption, ionic complexation) [5, 105].  As previously mentioned, 
surface adsorption approaches can result in rapid release of the growth factor and an inability to 
contain the growth factor to the local tissue environment due to diffusion away from the implant 
site [19, 30, 33]. On the contrary, when growth factors have a high affinity for the biomaterial, 
release tends to be limited.  For example, BMP-2 has a high affinity for calcium 
phosphate/hydroxyapatite type materials; in vitro release from these types of materials is usually 
very low (10-30%) [84, 106-108]. However, this is not necessarily undesirable; the high affinity 
to the scaffold material means the growth factor is readily available for cells to come into contact 
with the scaffold, providing a highly localized delivery [27, 109, 110]. Covalently immobilizing 
the growth factor to the scaffold can provide more prolonged release. This is because if the 
growth factor remains active after covalently tethering it to the biomaterial or scaffold then it 
will still activate the growth factor receptors on the cells, but it will be more slowly degraded and 
internalized [27]. A drawback to this approach is that covalently immobilizing the protein to the 
scaffold can result in conformation changes to the growth factor’s functional groups, resulting in 
its inactivation [111].  
 Physical encapsulation approaches include use of polymeric vehicles, hydrogels, and 
particles for delivery of growth factors. Polymers are advantageous for growth factor delivery 
because depending on the method of growth factor incorporation, release rate can be controlled 
by processes such as diffusion, charge interactions, erosion and degradation of the polymer, 
swelling of the polymer, or dissolution [112, 113]. Disadvantages to polymer delivery include 
denaturing and deactivation of proteins resulting from the encapsulation processes that usually 
require the use of harsh solvents, cross-linking agents and high temperatures [4]. 
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A way to physically entrap growth factors but to avoid high temperatures and harsh 
solvents is to utilize hydrogels [114]. Hydrogels are highly hydrated networks of cross-linked 
polymer chains formed from natural (collagen and hyaluronic acid), synthetic (polyethylene 
glycol) or semi-synthetic polymer backbones [115]. Growth factor delivery from hydrogels 
depends on the physiochemical properties of the polymer structure and the bioactive factor, and 
control over the growth factor delivery is usually dependent on the type and density of cross-
linkers [5]. A variety of materials have been used to produce hydrogels for single osteoinductive 
factor delivery including alginate [116, 117], gelatin [118, 119], fibrin [120], hyaluronic acid 
[79], and polyethylene glycol (PEG) [121]. Increasing the amount of cross-linking will decrease 
the degradation of the hydrogel and slow the release rate of the incorporated factor.  For 
example, in vitro and in vivo BMP-2 release from hydrogels was found to directly correlate to 
the density of cross-linkers and water content within the scaffold (cross-linkers released BMP-2 
through hydrolysis) [120, 122, 123].  A con to the use of hydrogels is that growth factor release 
is typically dependent on cross-linking; increasing the extent of cross-linking reduces the cyto-
compatibility of the hydrogel and can deactivate incorporated proteins [5].  Hydrogels are also 
limited to only being able to provide one rate of release at a time; therefore their use for 
multifactor delivery is limited to co-delivery.  Simmons et al. showed they could vary the 
degradation rate of their alginate hydrogel, therefore they could vary the release of rate of their 
incorporated factors either individually, or in combination, but they could not sequentially 
deliver the growth factors in combination [124]. 
A way to vary the release rates of multiple growth factors from a hydrogel is to make a 
composite material via the addition of particles to the hydrogel and/or scaffold with each 
component containing a different factor.  Encapsulation of growth factor via a micro- or 
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nanoparticle [125-129], or liposome [130] is a strategy commonly employed to provide sustained 
release and retain growth factor activity. Encapsulating a growth factor into a particle, then 
incorporating those particles into a hydrogel that also has an entrapped growth factor, is way to 
achieve two distinct release profiles for a multifactor delivery system [131, 132].  Sequential 
delivery from a system such as this is still difficult to achieve; this is because release of the 
particles from the hydrogel and release of the entrapped growth factor from the hydrogel are 
occurring simultaneously, but at different rates.  For true, sequential delivery, delayed release or 
delivery for at least one growth factor must be achievable through the biomaterial. 
1.1.6 Polyelectrolyte Multilayer Films 
A popular biomaterial strategy for multifactor delivery is the use of polyelectrolyte multilayer 
(PEM) films.  PEM is a layer-by-layer (LBL) build-up of oppositely charged polyelectrolytes, a 
polyanion (-) and polycation (+), to form a thin film.  PEM films were first introduced 20 years 
ago by Moehwald, Decher, and Lvov [133, 134] in attempts to produce thin films that could be 
used in biomedical applications to make surfaces more functionalized and render them more 
biomimetic. In the first 10 years of their introduction PEM films were only used in proof-of-
concept studies producing films containing small charged species such as biological molecules 
(polypeptides, polysaccharides, DNA, proteins, viruses) and various kinds of nanoparticles 
[135]. It was not until 2001 when the first study with a PEM film was used to observe the 
behavior of cells interacting with the coating [136].  In the past ten years, possibilities for the 
spatiotemporal control over cell growth and the use PEM films in vivo has been investigated 
[137].  
 As mentioned, PEM films are formed by alternately depositing oppositely charged 
polyelectrolyte that self-assemble and self-organize on a substrate’s surface.  For the most part 
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the LBL build up of PEM films relies on the electrostatic interactions between the 
polyelectrolytes, however non-electrostatic interactions, including hydrophobicity [138], 
hydrogen bonds [139], Van der Waals forces, halogen interactions [140], and covalent bonding 
[141] can influence the architecture of the film. The most common PEM application method is to 
dip coat the substrate [137], i.e. dip the substrate into the polyanion solution, rinse, dip into the 
polycation solution, rinse, etc.; however, PEM can also be applied via spray coating [142] or spin 
coating [143]. Dip coating requires rinse steps between polyelectrolyte application because the 
excess solution needs to be completely removed before application of the next polyelectrolyte 
otherwise the PEM will precipitate in solution rather than depositing onto the substrate as the 
next layer; spray coating removes the need of excess solution, therefore rinse steps can be 
skipped and accelerate the PEM application process [142]. 
 The growth of PEM films via LBL build up can be linear or exponential depending upon 
the polyelectrolytes used in the film. The original development of PEM films showed linear 
growth of film thickness with increasing number of layers deposited, and this growth is typical 
with use of polyelectrolytes such as poly(styrene sulfonate) (PSS) and poly(allylamine 
hydrochloride) (PAH) [144].  More recently exponential growth of film thickness with 
increasing number of layers deposited has been described with use of polyelectrolytes such as 
poly-L-Lysine (PLLys), alginate, and hyluronan (HA) [145, 146]. PEM films made up of 
polyamino acids and polysaccharides tend to result in exponential film growth [137], however 
even some synthetic polyelectrolytes such as polyacrylic acid (PAA) will also grow in this 
manner [147]. The use of natural polyelectrolytes, such as polyamino acids and polysaccharides, 
is desirable because these materials are biomimetic and have better biocompatibility in vivo. 
Exponential growth of PEM coatings is a result of “in and out” diffusion of the polyelectrolytes 
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[146].  As the film is exposed to a polyanion (-) solution, the polycation (+) within the film will 
diffuse to the surface allowing for more binding sites for the polyanion.  Vice versa will occur 
during the next step when the polycation solution is being applied.  This results in thicker and 
thicker layers of PEM being applied with each subsequent step.  In addition to the type of 
polyelectrolytes used, molecular weights of the polyelectrolytes can influence the “in and out” 
diffusion occurring within the film, thus influencing the exponential growth of the PEM film.  
Increasing the molecular weight of both synthetic polyelectrolytes (PAA in PAH/PAA film) 
[148] and natural polyelectrolytes (PLLys in PLLys/HA film) [149] restrained the ability of these 
polyelectrolytes to diffuse within the film. 
 The inter-diffusion of polyelectrolytes is now considered a “dominant” process involved 
with the use of PEM films, and this phenomenon is critical for understanding loading and release 
kinetics of bioactive molecules deposited into the films [137]. One of the most attractive features 
of PEM systems in their ability to retain the bioactivity of molecules incorporated into the films 
and to act as a reservoir for delivery of small molecules [150]. The layer-by-layer assembly 
technique allows for easy control over the order of which small molecules are incorporated into 
the film, and because the molecules are directly integrated in the architecture of the film via 
electrostatic interactions and do not require covalent bonding [151, 152], their secondary 
structures remain close to their native form and this retains their biological activity [111]. 
Because the incorporated molecules rely on electrostatic interactions within the PEM films, they 
too will diffuse throughout the PEM film during exponential film growth.  Vodouhe et al. 
showed that a fluorescently labeled molecule purposely adsorbed within one location of a 
PLLys/HA film, ultimately could be observed throughout the entire thickness of the film [153]. 
For single factor delivery from PEM films, this can be considered a desirable effect of the film 
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growth because the PEM now serves as a reservoir for the molecule.  In the same study, it was 
shown that increasing the film thickness increased the amount of drug that could be loaded into 
the PLLys/HA film [153]. 
 Issues with the exponential growth of PEM films become a problem when multiple small 
molecules are being incorporated into the film and the sequence of their release is trying to be 
controlled. Multiple factors can be adsorbed into PEM films at specific locations within the films 
but the “in and out” diffusion that occurs during the build up of the film will result in a blended 
architecture lacking controlled order, therefore resulting in uncontrolled delivery [154]. To 
prevent interlayer diffusion of molecules through exponentially growing PEM films, “blocking 
layers” can be added to act as barriers within the films.  These can include cross-linking layers 
within the film [147], using slowly degradable polymers such as poly(lactic-co-glycolic acid) 
within the film [155], or introducing a third component into the PEM film that acts as a physical 
barrier [156, 157].  The only way to achieve multifactor, sequential delivery from PEM films 
made with exponentially growing, biocompatible, polyelectrolytes is to prevent interlayer 
diffusion within the film. 
 The use of PEM films by themselves has been shown to aid in the biocompatibility of 
titanium implants interacting with osteoblast cells [158, 159]. In addition, individual and 
combinations of bioactive growth factors have been successfully delivered from PEM systems, 
including osteogenic factors such as FGF-2, TGFβ1, and BMP-2, and retained their bioactivity 
[160-167]. It was therefore decided that a PEM system could be developed for delivery of FGF-2 
and BMP-2 in hopes to stimulate osteogenesis for enhanced bone regeneration. 
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1.2 Specific Aims 
The goal of the research is to develop a biomaterial capable of sequential delivery of multiple, 
biologically active factors. The long-term goal is to develop a material that can sequentially 
deliver low dose FGF-2 and BMP-2 and be applied to a commercially available bone graft 
substitutes to enhance in vivo osteogenesis and potentially overcome clinical complications with 
high dose BMP-2. The successful biomaterial will deliver FGF-2 during the first few days of 
fracture healing, then deliver BMP-2; inflammation and osteoprogenitor 
recruitment/proliferation need to subside before delivering the differentiation agent from the 
biomaterial. The novelty of this work is the incorporation of a biomimetic calcium phosphate 
(bCaP) barrier layer into poly-L-lysine/poly-L-glutamic acid PEM design to prevent interlayer 
diffusion of growth factors resulting in a sequential, multifactor, bioactive delivery system that 
can be applied to two-dimensional (2-D) and three-dimensional (3-D) substrates. It is 
hypothesized that: If bCaP barrier layer can prevent diffusion of multiple factors within a 
PEM coating, then sequential delivery of factors can be achieved from a bCaP-PEM coated 
biomaterial. This objective will be completed with the following specific aims: 
Aim 1: Develop a biomimetic calcium phosphate-polyelectrolyte (bCaP-PEM) coating for 
sequential, multifactor delivery in vitro. Hypothesis: If bCaP barrier layer can prevent 
diffusion of multiple factors within a PEM coating, then sequential delivery of factors can be 
achieved from bCaP-PEM. Simulated body fluid (SBF) methods have been developed to form 
bCaP coatings on tissue culture plastic disks [168] that were utilized to achieve this aim. bCaP 
coatings are expected to provide a biocompatible barrier layer within the PEM design. Scanning 
electron microscopy (SEM), energy-dispersive x-ray spectroscopy, and x-ray diffraction were 
used to assess the morphology, composition, and structure the bCaP layer before and after PEM 
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application. To demonstrate sequential delivery a combination of a proliferative factor (FGF-2) 
and a cytotoxic factor (antimycin A) with opposing effects on MC3T3-E1 mouse calvarial 
osteoprogenitor cells were adsorbed into the coating to clearly demonstrate when cells were 
accessing the incorporated factors. Proliferative and cytotoxic effects were quantified using 
LIVE® staining (Invitrogen Life Technologies, Grand Island, NY) and ImageJ analysis. Release 
studies were conducted to determine if factors were released from the bCaP-PEM coating via 
diffusion. 
Aim 2: Demonstrate in vitro, cell-mediated delivery kinetics of multiple factors from the 
bCaP-PEM coating can be tuned by altering the structure/composition of the coating or 
changing the cell type used with the coating. Hypothesis: If delivery of the embedded factor is 
a function of coating thickness, then delivery kinetics of that factor can be further delayed by 
thickening the bCaP layer within the coating. Tunable delivery kinetics were assessed using the 
same MC3T3-E1 proliferation studies on coatings prepared with alterations made to the bCaP 
layer by increasing or decreasing time in the SBF solutions resulting in a thinner or thicker layer. 
Alternations to the PEM portion of the coating were also investigated to tune delivery kinetics of 
the incorporated factors via increasing the number of PEM bilayers and/or the use of D-
enantiomers polyelectrolytes. Additionally, delivery kinetics were assessed using RAW 264.7 
mouse macrophage cells to determine how cell type can change the cell-mediated 
degradation/delivery of the coating. 
Aim 3: Characterize bCaP-PEM coating applied to 3-D scaffolds, and determine the effects 
of sequential delivery of FGF-2 and BMP-2 on in vivo osteogenesis. Hypothesis: If sequential 
delivery of low dose FGF-2 and BMP-2 is a beneficial method of stimulating bone formation, 
then sequential delivery vs. co- or single factor delivery will result in increased in vivo 
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osteogenesis. The Kuhn lab previously demonstrated that sequential delivery of low dose FGF-2, 
followed by BMP-2 enhanced in vitro osteogenesis over co- or single factor delivery [88], 
therefore it is expected that this delivery sequence from bCaP-PEM would stimulate in vivo 
osteogenesis. SEM was used to access surface morphology and coating application of the bCaP-
PEM coating applied to a commercially available bone graft substitute scaffold. Sequential 
delivery of first FGF-2, then BMP-2 from bCaP-PEM applied to a scaffold was evaluated using 
an in vivo mouse calvarial defect model.  New bone formation 3-4 weeks post-surgery was 
assessed using x-ray and microCT.  Sequential delivery was compared to BMP-2 only delivery 
and the scaffold with no coating. 
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Chapter 2 
Biomimetic Calcium Phosphate/Polyelectrolyte Multilayer Coatings for Sequential Delivery of 
Multiple Biological Agents 
2.1 Introduction  
New multi-component biomaterial drug delivery systems are being developed to initiate 
multiple, critical aspects of the natural biological tissue regeneration process, including: infection 
control [1], as well as recruitment and migration [2] and proliferation and differentiation [3] of 
progenitor cells. These processes are governed in the body by the timely release and exposure to 
multiple growth factors [27, 36]. Therefore rather than being limited to the delivery of a single 
growth factor, biomaterial systems are needed to control the release of multiple therapeutic 
agents at optimized physiological doses, ideally with specific spatiotemporal patterns [6].  
Several different types of delivery systems for multiple growth factors have been 
developed as potential therapeutics for wound healing/infection, bone, cartilage, muscle, teeth 
and cancer, and have shown some efficacy both in vitro [1, 88, 131, 169, 170], and in vivo [101, 
167, 171]; however, their success has been limited.  The drawback of these systems, including 
microspheres [1], nanoparticles [169], and hydrogels [131, 171] is their co-delivery of factors. 
Growth factors have different effects on natural tissue regeneration depending on the 
developmental stage of the healing process they are present during; therefore, sequence of 
delivery is important to optimize growth factor activity and healing.  
A popular biomaterial strategy for multifactor delivery of growth factors or other 
biologically active molecules incorporates the use of polyelectrolyte multilayer (PEM) films.  
PEM is a layer-by-layer (LBL) build-up of oppositely charged polyelectrolytes, a polyanion (-) 
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and polycation (+).  These PEM films offer a means of temporal regulation of bioactive factors 
without loss of their biological activity [150]. In addition, the release kinetics of factors from 
PEM can be adjusted by alternating number of layers within the film, changing the type of 
polyelectrolytes [154], or introducing a third component/barrier layer [156, 157]. PEM can also 
be applied to two dimensional or three-dimensional porous, intricate substrates and scaffolds as 
thin films making PEM applications versatile. The layer-by-layer PEM delivery system is now 
widely being used for co-delivery of multiple factors; however, controlled, sequential delivery 
from PEM coatings has been limited due to problems associated with interlayer diffusion of 
incorporated factors within PEM [146, 154, 167].  
The novelty of the present study is the introduction of a biomimetic calcium phosphate 
(bCaP) barrier layer into a poly-L-Lysine (PLLys) and poly-L-Glutamic acid (PLGlut) PEM 
design.  Calcium phosphate was chosen because of its biocompatibility, low cost, and ease of 
manufacture. It was hypothesized that if the bCaP layer could prevent interlayer diffusion of 
biological agents, then controlled, sequential delivery of multiple factors would be achieved.  
This chapter reports the fabrication and characterization of bCaP-PEM coatings and the in vitro 
assessment of the sequential delivery kinetics and bioactivity of two factors with opposing 
activity (proliferative vs. cytotoxic) delivered from bCaP-PEM coatings. MC3T3-E1 
osteoprogenitor cells were used for the cell culture evaluation assays and biological assays were 
selected because they provide important information about the potential response of host 
progenitor cells to implanted materials coated with bCaP-PEM. 
Emily Elizabeth Jacobs – University of Connecticut, 2016 
 
 22 
2.2 Materials and Methods 
2.2.1 Design of the Sequential Delivery System 
To prevent the issue of interlayer diffusion of multiple factors associated with a PEM-only 
coating (Fig. 2.1A), a biomimetic calcium phosphate layer (bCaP) was incorporated into a 
PLLys-PLGlut PEM system, (Fig. 2.1B).  It is hypothesized that because of interlayer diffusion, 
a PEM only coating would result in co-delivery (Fig. 2.1C), but introducing bCaP into the 
delivery system would result in sequential delivery of multiple factors (Fig. 2.1D). 
2.2.2 Material Fabrication 
2.2.2.a Preparation of Biomimetic-CaP Disks 
Twenty-two mm diameter plastic disks (NUNC, Rochester, NY) were sandblasted with 240-grit 
aluminum oxide powder (Ivoclar Vivadent, Amherst, NY) to obtain a roughened surface 
(TCPsb). Both sides were roughened. The sandblasted disks were cleaned by ultra sonication in 
water and UV-sterilized prior to coating.  
A two-step simulated body fluid (SBF) biomimetic calcium phosphate coating (bCaP) 
protocol originally developed for metal substrates [118, 172-174] and modified for plastic disks 
by the Kuhn lab [168], was utilized to form the bCaP layer. The coating procedure involves 
immersion and incubation in two different solutions (Table 2.1): Solution A results in a thin 
amorphous layer of CaP, Solution B, with less inhibitors of apatite formation, results in the 
formation of mature apatite crystals as a second layer above the amorphous layer. Coatings were 
prepared with either just solution A (CaP) or solutions A and B (bCaP). All reagents (Sigma-
Aldrich) were used as received. 
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To prepare Solution A, the inorganic salts in the following order were weighed and 
dissolved in 800 ml sterile filtered MIlliQ water maintained at 37 ± 0.1°C with stirring: NaCl 
(32.0 ± 0.001 g), MgCl2, 6H2O (1.216 ± 0.001 g), CaCl2, 2H2O (1.472 ± 0.001 g). The pH was 
lowered to 4 by bubbling CO2 gas through the solution at a steady flow for about 5 min. Then 
Na2HPO4, 2H2O (0.712 ± 0.001 g) and NaHCO3 (1.408 ± 0.001 g) were dissolved and CO2 gas 
was continually bubbled through the solution until the pH was below 6.2.  At this point the 
solution was spilt in half between two smaller beakers (heated to 37°C), both capable of 
submerging three custom-made sample holders, each designed to hold 6 disks vertically, about 1 
mm apart. Vertical positioning was used to avoid the unwanted settling and attachment of any 
large homogeneously nucleated particles on the disks [175]. The beakers were sealed with saran 
wrap with 20–30 small holes in it to allow for gradual CO2 release, thus restricting homogeneous 
nucleation/solution precipitation that occurs without a cover, and promoting the formation of the 
thin amorphous CaP layer directly on the substrate disks. Each beaker was equipped with a stir 
bar and was placed in a 37°C oven on a stir plate set to match the mixing during the solution 
preparation (~130 rpm). After approximately 24 h, the samples were sonicated briefly in the 
reacted Solution A. Prior to immersion in Solution B, the disks were gradually dehydrated by 
being passed through a graded series of increasing concentrations of ethyl alcohol. 
To prepare Solution B, NaCl (32.0 ± 0.001 g), MgCl2, 6H2O (0.240 ± 0.001 g), CaCl2, 
2H2O (1.472 ± 0.001 g) were dissolved in 800 ml MilliQ water maintained at 50 ± 1°C followed 
by CO2 gas bubbling to obtain a pH below 4.0. Na2HPO4, 2H2O (0.712 ± 0.001 g) and NaHCO3 
(0.704 ± 0.001 g) were added and CO2 gas was bubbled through the solution until 
supersaturation at a pH of 5.8–6.2 was reached. The solution was then split, the disks were 
immersed, and the beakers sealed as before to limit homogeneous nucleation, and placed in a 
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50°C oven. The process was allowed to proceed for at least 24 h with stirring, until the pH was > 
7.8 at which time the samples were removed, sonicated briefly in the reacted Solution B, then 
dehydrated in a series of graded ethanol. The samples were stored in a desiccator until further 
use. 
2.2.2.b Polyelectrolyte multilayer application 
The PEM coatings were applied to the sandblasted plastic disks, CaP- and/or the bCaP-coated 
disks by alternate 10 min dippings into 1 mg/ml poly-L-Glutamic acid (PLGlut-) or poly-L-
Lysine (PLLys+) solutions (Sigma, St. Louis, MO), with seven saline rinses between each.  This 
dip-coating process was automated with the use of a histology-staining machine (Varistain 24-4, 
Thermo Shandon, Loughborough, UK) and custom designed sample holders. Eight or thirty 
bilayers (PLLys-PLGlut = 1 bilayer) were adsorbed on top of the disks.  The coated disks were 
UV-sterilized on both sides prior to cell culture. 
2.2.2.c Factor Application 
To demonstrate the ability of bCaP addition to PEM to prevent diffusion and delay access to an 
embedded factor, a model cytotoxic agent antimycin A (AntiA) (213 μg/disk) (Sigma, St. Louis, 
MO) was used.  Prior to bCaP and/or PEM application, 10 μl of 40mM AntiA in ethanol (213 
μg/disk) was adsorbed onto the sandblasted plastic surface, and allowed to dry; since AntiA was 
allowed to completely dry to maximize binding.  The disks were rinsed 3x with saline before 
coating application.  During the coating application the disks were protected from light. 
To demonstrate sequential delivery from the bCaP-PEM coatings, a combination of a 
proliferative factor, recombinant human fibroblast growth factor-2 (FGF-2) (150 ng/disk) (R & 
D Systems, Minneapolis, MN), and the cytotoxic AntiA was used.  The AntiA (213 μg/disk) was 
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embedded beneath the coating.  After AntiA adsorption, bCaP and PEM30 application, 375 
ng/ml FGF-2 in saline was allowed to adsorb to the coated disks for 1hr, then rinsed 3x with 
saline.  Enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN) testing 
was performed and determined approximately 80% FGF-2 binds, (actual adsorbed dose ~120 
ng/disk).  
The coating procedure is summarized in Figure 2.2 including factor application, calcium 
phosphate deposition, and PEM adsorption. Factor 1 represents FGF-2, the factor to be delivered 
first, and Factor 2 represents AntiA, the embedded factor to be delivered at a later time point. 
2.2.3 Characterization  
2.2.3.a Scanning Electron Microscopy (SEM) 
One CaP, bCaP, bCaP-PEM, and PEM coated disks from 3-6 different batches were examined to 
characterize surface morphology and consistency. The microscopic morphology was 
characterized using SEM (JSM - 5900LV, Jeol USA Inc. Peabody, MA). Disks were cut in half, 
allowing examination of the coating cross-section and measurement of the coating thickness in 
multiple locations.  
2.2.3.b Energy Dispersive X-Ray Spectroscopy (EDS) 
The elemental composition and Ca/P ratio of the bCaP coatings before and after PEM application 
were determined with energy dispersive X-ray spectroscopy (FEI Teneo LVSEM and EDAX 
SDD EDS). The accelerating voltage was 10 kV and the depth of X-ray interaction was 
estimated to be 1 μm. At least 3–5 locations on each disk were analyzed at 1kX magnification for 
an area scan, and 10kX for point analysis. Values were compared to those obtained from a 
hydroxyapatite powder (Sigma, St. Louis, MO). 
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2.2.3.c X-Ray Diffraction (XRD) 
The crystal structure of the bCaP coating before and after PEM application was determined with 
an X-ray diffractometer (Bruker D8 Advanced, Bruker AXS) using Cu Kα radiation at 40 kV and 
44 mA over a 2θ range of 5–75◦ at a scan rate of 2°/min in steps of 0.02°. Sufficient material was 
scraped from six representative disks to produce powder samples. The crystal structure was 
identified by comparison to the hydroxyapatite standard and previously published patterns [168]. 
2.2.3 Cell Culture Assays  
MC3T3-E1 mouse calvarial osteoprogenitor cells (ATCC, Manassas, VA) were cultured in 
alpha-Minimal Essential Medium (α-MEM, No. 12571, Gibco BRL, Invitrogen), supplemented 
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate. 
Medium was refreshed every 2–3 days until 80-90% confluent and split at a ratio of 1:8. 
Passages 10–30 were routinely used. The cells were detached from tissue culture dishes with 
0.25% trypsin and 1 mM EDTA (Invitrogen, Cat. No. 25200-056) at 37°C. Cells were counted 
using an automated cell counter (Bio-Rad, TC20) with trypan blue staining to assess cell number 
and viability prior to the cell proliferation assays. 
The coated disks were sterilized prior to cell culture by exposure to UV light for 10 min 
to each side of the disks.  They were then placed into 12-well treated tissue culture plates 
(Corning Inc., Corning, NY) and submerged in α-MEM medium for 30-45 min. MC3T3-E1s 
were seeded at 1 or 4 x 104 cells/cm2 in culture medium and were incubated at 37°C and 5% CO2 
for up to 7 days with medium changed every 3 days. Proliferative and cytotoxic effects of the 
coatings on the cells were evaluated with LIVE® staining (Invitrogen Life Technologies, Grand 
Island, NY) following the manufacturer’s protocol.  Prior to LIVE® staining the disks were 
transferred to new wells and washed with phosphate buffered saline solution (PBS) to remove 
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non-adherent cells; LIVE® staining was prepared as instructed and applied to the disks, and then 
incubated at room temperature for 30 min. After 30 min disks were flipped over and imaged at 
100X magnification using an inverted microscope (TE300, Nikon) equipped with a camera 
(Diagnostic Instruments), and imaging software (Spot Insight, Nikon).  ImageJ was used for 3-5 
images/well, analysis of 3-6 wells/group. Proliferation was quantified as average percent 
fluorescent area via ImageJ analysis. Percent cell death was calculated by comparing the average 
percent fluorescent area of the AntiA group to its AntiA-free control. 
2.2.3.a Antimycin A Dose Response and Stability 
The embedded factor (“Factor 2”) used to assess diffusion prevention was antimycin A (AntiA) 
(Sigma, St. Louis, MO), known to be cytotoxic to MC3T3-E1 cells [176, 177].  To determine the 
appropriate cytotoxic dose when delivered from a biomaterial surface a dose response study was 
first conducted. The following doses of AntiA were absorbed in 10 μl volumes of ethanol to 12-
well treated tissue culture plates (Corning Inc., Corning, NY): 40 mM, 20 mM, 12 mM, 6 mM, 2 
mM, 0.07 mM, and 0 mM (100% ethanol), n = 3 wells/dose.  AntiA solution was allowed to 
completely dry on the wells to maximize binding. After drying, wells were rinsed 3x with saline 
and then placed in α-MEM medium for 30-45 min prior to plating.  MC3T3-E1s were plated at 1 
x 104 cells/cm2. Cytotoxic effects of the adsorbed doses on the cells were evaluated with LIVE® 
staining after 24 h of culture. ImageJ analysis was performed.   
 To determine if the coating process inactivated the AntiA, 10 μl of 40mM AntiA in 
ethanol (213 μg/disk) was adsorbed onto the sandblasted disks, allowed to dry, and then rinsed 
3x with saline.  N = 4 disks underwent the “PEM” processing but without PEM, meaning disks 
were subjected to the automated dip procedure that normally would apply the polyelectrolytes 
but only saline was used.  N = 4 disks underwent conditions similar to the “bCaP” processing, 
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meaning the disks were submerged in MilliQ water (rather than solution A or B) and left in the 
oven at 37°C for 24 h, then at 50°C for 24 h.  After “processing” disks were placed in 12-well 
plates.  Fresh AntiA adsorbed to sandblasted disks (213 μg/disk with 3x saline rinses, n = 4) was 
used as a positive control.  Sandblasted disks with no AntiA were used as the negative control (n 
= 4). MC3T3-E1s were plated at 4 x 104 cells/cm2. Cytotoxic effects of the disks on the cells 
were evaluated with LIVE® staining after 24 h of culture. ImageJ analysis was performed.   
2.2.3.b Diffusion Studies 
AntiA was used as “Factor 2” to evaluate if prevention of interlayer diffusion of an embedded 
factor could be achieved by the addition of CaP and/or bCaP to PEM. Coatings were prepared as 
previously described in section 2.2.2c. The following groups/coatings were used for the diffusion 
studies and repeated at least 2x: TCPsb, TCPsb-AntiA, and TCPsb coated with CaP-PEM8, 
AntiA-CaP-PEM8, CaP-PEM30, AntiA-CaP-PEM30, bCaP-PEM30, AntiA-bCaP-PEM30, 
PEM30, and AntiA-PEM30. MC3T3-E1s were seeded at 1 or 4 x 104 cells/cm2 in culture 
medium and were incubated at 37°C and 5% CO2 for up to 5 days. LIVE ® staining with ImageJ 
analysis was performed. 
2.2.3.c FGF-2 Dose Response 
FGF-2 was selected as Factor 1 for evaluating the bCaP effects on diffusion. FGF-2 stimulates 
MC3T3-E1 proliferation [36, 88, 178, 179], and has the opposite effect of Factor 2 (cytotoxic 
AntiA) on the cells.  The following doses of FGF-2 were adsorbed to bCaP-PEM30 coated disks, 
0, 1.5, 15, and 150 ng/disk as previously described in section 2.2.2c. MC3T3-E1s were seeded at 
4 x 104 cells/cm2 in culture medium and were incubated at 37°C and 5% CO2 for 1 day. LIVE ® 
staining with ImageJ analysis was performed on day 1. 
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2.2.3.d Bioactivity of Single Factor Delivery from bCaP-PEM30 
The bioactivity of Factor 1 (150 ng/disk FGF-2) and Factor 2 (213 μg/disk AntiA) delivered 
from bCaP-PEM30 coated disks were investigated individually. Coatings were prepared as 
previously mentioned, and MC3T3-E1s were plated at 4 x 104 cells/cm2 in culture medium and 
were incubated at 37°C and 5% CO2 for up to 5 days with medium changed on day 3. LIVE ® 
staining with ImageJ analysis was performed on 4h, day 1, 2, 3, 4, and 5. All groups were 
repeated twice. 
2.2.3.e Sequential Delivery from bCaP-PEM30 
The sequential delivery (AntiA-bCaP-PEM30-FGF2) coated disks and their controls (bCaP-
PEM30-FGF2) were prepared as previously mentioned. MC3T3-E1s were plated at 4 x 104 
cells/cm2 in culture medium and were incubated at 37°C and 5% CO2 for up to 5 days with 
medium changed on day 3. LIVE ® staining with ImageJ analysis was performed on 4h, day 1, 
2, 3, 4, and 5. All groups were repeated at least twice. 
2.2.4 Factor Release from bCaP-PEM30 Coatings 
AntiA-bCaP-PEM30-FGF2 and bCaP-PEM30-FGF2 coatings were prepared on TCPsb. Coated 
disks were incubated in culture medium at 37°C and 5% CO2 for 1 or 3 days without cells or 
media changes.  Release medium was collected at each time point and immediately frozen at -
20°C.  MC3T3-E1s were plated in a 96-well tissue culture treated plate (Becton Dickinson and 
Company, Franklin Lakes, NJ) at 2.5 x 103cells/cm2.  After 48 h of culture, 50% of the media in 
each well was removed and replaced with thawed release medium (in triplicate).  After an 
additional 24 h of culture LIVE® staining and ImageJ were used to determine the effects of the 
release medium on the culture. Enzyme-linked immunosorbent assay (ELISA, R&D Systems, 
Minneapolis, MN) testing was also performed on FGF-2 group release samples.   
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2.2.5 Statistical Analyses 
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey 
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations 
are shown in all figures. 
2.3 Results 
2.3.1 Characterization of the Coatings 
SEM microscopy with EDS point analysis revealed some embedded aluminum oxide used for 
sandblasting the disks present on the sandblasted plastic disks (Fig. 2.3A). The CaP coating 
produced with Solution A only resulted in a uniformly deposited, thin, amorphous layer.  The 
CaP layer was so thin it could not be measured via SEM (Fig. 2.3B).  The bCaP coating 
produced with both solution A and solution B resulted in densely packed, nano-crystals that 
completely coated the TCPsb.  The average layer thickness measured via SEM was 5.8 + 1.8 μm 
(Fig. 2.3C). The bCaP crystals became indistinguishable after PEM30 application with an 
average bCaP-PEM30 coating thickness of 16.3 + 2.2 μm (Fig. 2.3D). PEM30 uniformly 
adsorbed to the TCPsb, but the coating thickness was not measurable via SEM (Fig. 2.3E). 
Energy dispersive x-ray spectroscopy (EDS) revealed Ca/P atomic ratios of 1.95 + 0.12 
and 1.52 + 0.50 for bCaP before (Fig. 2.4A) and after PEM30 adsorption (Fig. 2.4B), neither of 
which is statistically different than the Ca/P ratio of the hydroxyapatite powder, (1.71 + 0.04), 
nor each other (Fig. 2.4C). EDS analysis of bCaP-PEM30 also confirmed the presence of carbon 
and nitrogen due to the polyelectrolyte compositions. The crystal structure of the bCaP was 
identified as poorly crystalline/nanocrystallline hydroxyapatite by XRD (Fig. 2.4D). The term 
poorly crystalline/nanocrystalline is used due to the observed peak broadening [168]. After PEM 
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adsorption, the bCaP crystal structure became less crystalline as evident by even further peak 
broadening (Fig. 2.4E). 
2.3.2 Antimycin A Dose Response and Stability 
The antimycin A dose response study revealed a 50% inhibitory concentration (IC50) of 3.08 
mM (Fig. 2.5).  The 40 mM dose (213 μg/disk) resulted in almost complete cell death; therefore, 
it was selected to be used in all studies that use AntiA because it was necessary to observe 
significant cell death to ensure there were no question the cells were accessing the AntiA. 
 To ensure the coating procedure did not inactivate the AntiA, antimycin’s stability was 
tested after being treated with multiple saline rinses (“PEM” processing), or when treated with 
MilliQ water and heat (“bCaP” processing).  All AntiAs tested resulted in significant cell death 
within 24 h of culture as compared to the negative control, TCPsb with no AntiA (Fig. 2.6, **** 
p < 0.0001).  Furthermore there were no statistically significant differences between the 
processed AntiAs compared to the fresh/normal AntiA indicating AntiA retains its cytotoxic 
activity after coating application. 
2.3.3 Diffusion Studies 
The first attempt at producing a coating that could prevent the interlayer diffusion of embedded 
213 μg/disk AntiA was to use an amorphous CaP layer and 8 bilayers of PEM (CaP-PEM8). Day 
1 LIVE® staining of MC3T3-E1s cultured on TCPsb coated with AntiA, AntiA embedded under 
PEM8, and AntiA embedded under CaP-PEM8 resulted in 91.9 + 2.3 %, 79.6 + 5.2 %, and 42.4 
+ 2.8 % cell death respectively, relative to their AntiA-free controls (Fig. 2.7A).  Though CaP-
PEM8 was significantly better than the PEM8 coating at preventing diffusion of AntiA (**** p 
< 0.0001), it did not provide enough delayed access to the embedded AntiA as indicated by the 
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significant difference between AntiA-CaP-PEM8 and CaP-PEM8 at day 1 (Fig. 2.7B, **** p < 
0.0001). 
 The next attempt to improve delayed access to the embedded 213 μg/disk AntiA was to 
increase the number of PEM bilayers adsorbed to the CaP layer from 8 to 30. This resulted in no 
difference between AntiA-CaP-PEM30 and CaP-PEM30 on day 1, however, no drop in LIVE® 
staining with extended time in culture was observed (Fig. 2.8).   
It was then decided to increase the thickness and crystallinity of the CaP layer by using 
both Solution A and Solution B to make bCaP in attempts to prevent diffusion and completely 
block access to the AntiA in the first day. MC3T3-E1s cultured for one day on TCPsb coated 
with 213 μg/disk AntiA resulted in a significant drop in % LIVE® stained area as compared to 
its AntiA-free control (TCPsb vs. TCPsb+AntiA, Fig. 2.9A, **** p < 0.0001), and this equated 
to 96.6 + 1.2 % cell death (Fig. 2.9B); this is visualized in Fig. 2.9C vs. D. MC3T3-E1s cultured 
for one day on TCPsb coated with 213 μg/disk AntiA embedded under 30 bilayers of PEM 
resulted in a significant drop in % LIVE® stained area as compared to its AntiA-free control 
(PEM30 vs. PEM30+AntiA, Fig. 2.9A, *** p < 0.001), and this equated to 79.5 + 4.2 % cell 
death (Fig. 2.9B); this is visualized in Fig. 2.9E vs. F. MC3T3-E1s cultured for one day on 
TCPsb coated with 213 μg/disk AntiA embedded under bCaP and 30 bilayers of PEM resulted in 
no difference in % LIVE® stained area as compared to its AntiA-free control (bCaP-PEM30 vs. 
bCaP-PEM30+AntiA, Fig. 2.9A), and this equated to -6.7 + 10.6 % cell death (Fig. 2.9B); this is 
visualized in Fig. 2.9G vs. H. Percent cell death is negative for this group because the day 1 
LIVE® staining on the AntiA-bCaP-PEM30 was slightly higher than on the bCaP-PEM30 
control, (Fig. 2.9A). 
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2.3.4 Bioactivity of Single Factor Delivery from bCaP-PEM30 
Figure 2.10 displays the results of day 1 LIVE ® of MC3T3-E1s cultured on bCaP-PEM30 
coated disks with various doses of FGF-2.  Because the 150 ng/disk dose of FGF-2 had the most 
significant effect on cell proliferation (**** p < 0.0001), it was selected as the dose to be used 
for all future coating studies. 
Factor 1 (150 ng/disk FGF-2) and Factor 2 (213 μg/disk AntiA) location within the bCaP-
PEM30 coating and the expected cell access profiles are illustrated in Figure 2.11. Bio-active 
FGF-2 was successfully delivered from bCaP-PEM30 coated disks (bCaP-PEM30-FGF2) as 
indicated by the significant increase in LIVE® staining of the MC3T3-E1 cultures on day 1 and 
the remaining time points in the study, as compared to the FGF-free control (bCaP-PEM30) (Fig. 
2.12). No differences were observed at 4 h (Fig. 2.13). Active AntiA was successfully delivered 
from bCaP-PEM30 coated disks (AntiA-bCaP-PEM30) as evident by the significant decrease in 
MC3T3-E1 proliferation on day 3 as compared to the AntiA-free control (bCaP-PEM30) (Fig. 
2.14).   
2.3.5 Factor Release from bCaP-PEM30 Coatings 
Release medium collected from bCaP-PEM30-FGF-2 coated disks incubated without cells for 1 
and 3 days had no significant proliferative effect on MC3T3-E1s as compared to controls 
cultured in normal medium, indicating no FGF-2 release (Fig. 2.15, D1 and D3 –A/+F). Release 
medium collected after 1 and 3 days incubation with AntiA-bCaP-PEM30-FGF-2 had no 
cytotoxic effect on cells as compared to release medium collected after 1 and 3 days incubation 
with bCaP-PEM30-FGF-2 indicating no AntiA release (Fig. 2.15, D1 and D3 +A/+F). 
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2.3.6 Sequential Delivery of Multiple Factors from bCaP-PEM30 Coatings 
Active FGF-2 (150 ng/disk) was delivered from bCaP-PEM30 coated disks with or without 
embedded AntiA as evident by the significant increase in day 1 MC3T3-E1 LIVE® staining of 
the FGF-2 groups as compared to their FGF-2-free controls, (Fig 2.16A). No differences in 
LIVE® stained area were observed between cells cultured on bCaP-PEM-FGF2 and AntiA-
bCaP-PEM30-FGF2 for time points 4h, day 1 and day 2, as both groups were exposed to FGF-2 
and AntiA was successfully being blocked (Fig. 2.16B, 3.3C); by day 3 a significant decrease in 
LIVE® staining between groups was observed indicating AntiA delivery, (Fig. 2.16B, 3.3C).  At 
day 4, the cells that survived the AntiA exposure started to recover and continued to proliferate 
through the duration of the study (Fig. 2.16C). 
2.4 Discussion 
There is a need for new biomaterials to deliver bioactive growth factors in a sequential manner to 
maximize their reparative effects. In this study the development of a novel biomimetic calcium 
phosphate/polyelectrolyte multilayer coating for the sequential delivery of multiple biological 
agents was reported. In vitro studies were used to demonstrate the ability of the bCaP barrier 
layer to prevent the interlayer diffusion problem associated with PEM films. Two different 
factors were delivered without loss of activity, and the delivery of factors from the coating was 
cell-mediated. Most importantly sequential delivery of multiple factors was demonstrated. 
The polyelectrolyte multilayer films formed by PLLys and PLGlut occurs by exponential 
growth with “in and out” diffusion of the polyelectrolytes that allow interlayer diffusion of 
incorporated factors [146].  As the film is exposed to a polyanion (-) solution, the polycation (+) 
within the film will diffuse to the surface allowing for more binding sites for the polyanion.  Vice 
versa will occur during the next step when the polycation solution is being applied; because of 
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this growth pattern, any incorporated factor within the film will constantly be rearranged during 
the layer build up resulting in a blended architecture lacking controlled order, therefore 
uncontrolled delivery [154] (Fig. 2.17). To prevent this diffusion from occurring a biomimetic 
calcium phosphate layer was incorporated into the poly-L-Lys/poly-L-Glut acid PEM design to 
act as a barrier and keep the factors in separate locations within the coating so sequential delivery 
could be possible.  The combined use of polyelectrolytes and CaP has previously been 
investigated for bone tissue engineering, but not as a multifactor delivery system [157, 180, 181]. 
It was observed that the addition of an amorphous CaP layer could significantly improve 
interlayer diffusion of embedded antimycin A as compared to a PEM only coating, however, 
42% of the cells still accessed at least some of the AntiA within the first 24 h resulting in their 
death (Fig 2.7A).  The CaP-PEM8 coating would be insufficient for sequential delivery because 
the embedded Factor 2 can still be accessed immediately.  Increasing the number of PEM 
bilayers in attempts to prevent cellular access to the embedded AntiA had little to no effect, 
again suggesting that a CaP-PEM30 coating would also be insufficient for potential sequential 
delivery.  The data indicates that the MC3T3-E1s can access the embedded AntiA within the first 
24 h and implies the CaP and PEM30 coatings were too thin; in fact they were not capable of 
being measured via SEM (Fig. 2.3B, E). 
To completely block access of the cells to the embedded AntiA for at least 1 day, it was 
hypothesized that increasing the thickness of the CaP layer would not only prevent the diffusion 
of the AntiA up and into the PEM layers, but delay access to the AntiA. It was shown that 30 
bilayers of PEM delays access to embedded AntiA better than no coating at all, but it still results 
in significant cell death within 24 h (Fig. 2.9B).  PEM alone could not inhibit the embedded 
AntiA from diffusing up and through the bilayers, resulting in immediate access of the cells to 
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the cytotoxic factor.  However, when the AntiA is embedded beneath the bCaP layer and 30 
bilayers of PEM, almost no cell death occurs by 24 h (Fig. 2.9B).  These results confirm that a 
PEM30 only coating would be insufficient for sequential delivery because it cannot inhibit 
interlayer diffusion; but the addition of bCaP to the PEM30 coating successfully inhibits 
diffusion, and prevents access at day 1, suggesting the potential of this coating design for 
sequential, multifactor delivery.  
The PEM system has the ability to release and maintain the bioactivity of the 
incorporated factors. Because bioactive proteins are directly integrated in the architecture of the 
film based on electrostatic interactions and do not require covalent bonding [151, 152], their 
secondary structures remain close to their native form and this retains their biological activity 
[111].  Individual and combinations of bio-active growth factors have been successfully 
delivered from PEM systems [160, 163, 165-167]; more specifically, TGFβ1, BMP-2, VEGF, 
and BMP-2 antagonist (Noggin) have all been delivered from poly-L-Lysine/poly-L-Glutamic 
acid PEM coatings and retain their bioactivity [161, 162, 164].  Other delivery systems, such as 
polyethylene glycol (PEG) hydrogels, can inactivate the protein during the immobilization 
process (crosslinking) via damaging the growth factor’s functional groups [27]. 
It was shown in the present study that delivery of FGF-2 from the bCaP-PEM coating 
causes significant increase in MC3T3-E1 proliferation confirming that the biological activity of 
FGF-2 is retained and being delivered in the therapeutic range (Fig. 2.12). It should be noted that 
FGF-2 did not aid in initial cell attachment, as evident by the lack of significant differences in 
LIVE® staining of the MC3T3-E1s after 4 h of culture (Fig. 2.13A).  It was only after 24 h that 
an increase was observed (Fig. 2.13B) indicating that the FGF-2 is stimulating the proliferation 
of the MC3T3-E1s.  Literature suggests that FGF-2 will aid in initial cell attachment [182], 
Emily Elizabeth Jacobs – University of Connecticut, 2016 
 
 37 
however it is hypothesized that the PEM bilayers act as a reservoir for the FGF-2; even though 
the FGF-2 is adsorbed as the outermost layer of the coating, it is believed that the FGF-2 will 
diffuse down into the PEM layers. Because of this, cells may not be immediately in contact with 
the FGF-2, which could explain why no differences are observed after 4h; however, after 24 h 
and time for the cells to start to degrade the PEM, they gain access to the FGF-2 that stimulates 
their proliferation.   The cytotoxic activity of AntiA is also retained after it is accessed on day 3 
of culture on the AntiA-bCaP-PEM30-FGF2 group (Fig. 2.14). 
One of the most attractive features of the bCaP-PEM delivery system is its ability to 
locally deliver factors directly to cells and thereby restrict therapeutic action to a small domain of 
tissue. Poly-L-Lysine/poly-L-Glutamic acid PEM allows for local delivery of incorporated 
factors because release depends upon cell-mediated enzymatic degradation of the PEM layers 
[150], and not diffusion of the factors out of the coating.  In systems where the growth factor is 
simply mixed with a carrier, or adsorbed on the surface without an additional coating, burst 
release of the growth factor leads to diffusion away from the target site and it can be 
enzymatically digested or deactivated [6], or can require supraphysiological doses of growth 
factor that lead to off-target, unwanted side effects, (INFUSE Bone Graft (Medtronic) [19, 30].  
Encapsulating the growth factor within a liposome or particle can extend the release and prevent 
the deactivation of the growth factor [130, 183]; however, the delivery system is still dependent 
on diffusion of the particles out of a secondary material therefore local, targeted delivery to only 
the cells of interest can be difficult to achieve. In the present studies there was no indication of 
release of neither FGF-2, nor AntiA without cells present. There was a lack of measurable 
quantities of FGF-2 in the release medium and no proliferative or cytotoxic effects of the release 
medium collected from disks incubated without cells was observed (Fig. 2.15). Due to the cell-
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mediated degradation of the bCaP-PEM coating, lower doses of growth factor can be used 
because delivery is not dependent on diffusion. AntiA has low solubility in solutions other than 
ethanol; therefore it was unlikely the AntiA would diffuse into an aqueous release medium, 
which may be why no indication of release without cells present was observed.  However, AntiA 
has a known 50% inhibitory concentration against MC3T3-E1 cells of 70 μM when in solution 
[176]; in the present studies a 40 mM dose of AntiA before bCaP-PEM30 coating was used. 
Even if a fraction of this dose were diffusing out of the coating into the media, it would be 
expected to have a cytotoxic effect on the cells.   
The mechanism of which the MC3T3-E1 cells degrade the bCaP to access the AntiA 
remains unclear.  In the Kuhn’s lab previous work, it was shown that after 21 days of MC3T3-E1 
cultured on the bCaP coating, the coating remained intact [168]. It is hypothesized that rather 
than physically degrading the bCaP layer, the MC3T3-E1s are actually using their processes to 
push through small cracks in the coating and access the AntiA.  It is known that osteoblasts 
cultured in three-dimensions [184] or on the surface of bone will form long processes [185, 186]. 
From the LIVE® staining in the present studies, it is evident the MC3T3-E1s have processes in 
two-dimensions along the surface of the coating; it is hypothesized these processes also extend 
down through the coating and that is how the AntiA is being accessed. 
Sequential delivery of multiple bioactive factors with complete blocking of access to the 
embedded factor for three days was demonstrated by introducing a bCaP barrier layer into a 30-
bilayer poly-L-lysine/poly-L-glutamic acid PEM system (Fig. 2.16). As previously mentioned, 
Min et al. used a similar barrier layer strategy for attempted sequential delivery from a PEM 
coating and demonstrated successful staggered release of first an antibiotic and then BMP-2. 
Burst release of BMP-2 was prevented and sustained release was demonstrated for several days, 
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but measurable released BMP-2 was still present at their earliest time points [156].  In a dual-
purpose delivery system such as this, where the factors do not influence each other and serve two 
separate functions (prevent infection, aid in bone healing), this delivery profile is acceptable.  
However in a system where the growth factors are being delivered in combination for one 
function, such as the use of FGF-2 and BMP-2 for enhanced bone regeneration, sequential 
delivery may be necessary because these growth factors can influence the effect of the other. 
2.5 Conclusions 
This study showed that a poly-L-Lysine/poly-L-Glutamic acid PEM only coating results in 
interlayer diffusion and immediate access to an embedded factor, proving that this PEM only 
system could not provide sequential delivery of multiple factors. The addition of amorphous CaP 
to PEM prevented some interlayer diffusion of an embedded factor, however significant access 
to the factor was occurring with 24 h, suggesting it would be incapable of sequential delivery. 
The addition of nanocrystalline bCaP to PEM (bCaP-PEM30) completely prevented unwanted 
interlayer diffusion of the embedded factor and enabled cell-mediated sequential delivery of 
multiple factors. Sequential delivery of a proliferative factor, fibroblast growth factor-2, followed 
by a cytotoxic factor, antimycin A was demonstrated. Both factors retained their bioactivity in 
vitro. The addition of the bCaP layer to the PEM design resulted in delayed access of the 
embedded antimycin A out to 3 days when cultured with MC3T3-E1 cells.  This delivery system 
has potential to endow biomaterial scaffolds with the ability to mimic natural biological 
processes that involve a sequential delivery profile activated by cell degradation of matrix. 
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Figure 2.1 Schematic representation of interlayer diffusion of Factors 1 and 2 in a PEM only 
coating (A), compared to prevention of interlayer diffusion of Factors 1 and 2 with the addition 
of bCaP to the PEM coating (B). The theoretical co- and sequential delivery profiles from a PEM 
only coating (C) and a bCaP-PEM coating (D) respectively. 
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Table 2.1 Nominal chemical composition of Solutions A and B in mM.  Solution B contains less 
inhibitors of apatite crystal formation (red text). 
Inorganic Salt Solution A Solution B Reagent Chemical 
Na+ 733.5 733.5 NaCl 
Mg2+ 7.5 1.5 MgCl2  6H2O 
Ca2+ 12.5 12.5 CaCl2  2H2O 
Cl- 720 720  
HPO4
2- 5 5 Na2HPO4  2H2O 
HCO3- 21 10 NaHCO3 
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Figure 2.2 Sandblasted disk coating procedure for diffusion studies.  Step 1: Factor 2 (AntiA) is 
adsorbed. Step 2A: disks are submerged in Solution A to deposit a thin layer of amorphous 
calcium phosphate (CaP). Step 2B: disks are submerged in Solution B to deposit nanocrystalline 
calcium phosphate, (bCaP). Step 3: 8-30 bilayers of PEM are applied by automated dip 
procedure. Step 4: Factor 1 (FGF-2) is adsorbed. 
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Figure 2.3 Scanning electron microscopy images of the surface morphology and cross-section of 
a sandblasted disk (A), and the sandblasted disks coated with: amorphous calcium phosphate 
CaP (B), nanocrystalline calcium phosphate bCaP (C), nanocrystalline calcium phosphate and 30 
bilayers of PEM (D), and 30 bilayers of PEM (E). B and E coating thickness was not measurable 
via SEM.  bCaP thickness = 5.8 + 1.8 μm (C). bCaP-PEM30 thickness = 16.3 + 2.2 μm (D). 
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Figure 2.4 EDS analysis of the bCaP deposited on the TCPsb before (A) and after PEM30 
adsorption (B), revealed Ca/P atomic ratios of 1.95 + 0.12 and 1.52 + 0.50 respectively, not 
statistically different from the hydroxyapatite powder (1.71 + 0.04) nor each other. The 
composition of the bCaP coating was identified as poorly crystalline/nanocrystalline 
hydroxyapatite by XRD (C).  After PEM adsorption the bCaP became less crystalline (D).  
  
Emily Elizabeth Jacobs – University of Connecticut, 2016 
 
 46 
 
Figure 2.5 AntiA dose response curve.  The adsorbed AntiA IC50 was found to be 3.08 mM 
(black arrow).  The dose of AntiA selected to use for all studies was 40 mM (red arrow).   
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Figure 2.6 Percent LIVE® stained area of MC3T3-Es cultured for 1 day on sandblasted disks 
coated with normal AntiA (TCPsb-AntiA), AntiA after “PEM” processing, AntiA after “bCaP” 
processing, and no AntiA (TCPsb). AntiA = 213 μg/disk. (**** p < 0.0001). 
ANOVA P value < 0.0001 
 
  
Tukey's multiple comparisons 
test 
Mean 
Diff. 
95% CI of diff. Significant? Summary 
TCPsb vs. TCPsb-AntiA 34.26 28.20 to 40.32 Yes **** 
TCPsb vs. TCPsb-AntiA 
"PEM" Processed 
34.35 28.29 to 40.41 Yes **** 
TCPsb vs. TCPsb-AntiA 
"bCaP" Processed 
30.43 24.36 to 36.49 Yes **** 
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Figure 2.7 Day 1 percent cell death of MC3T3-E1s cultured on TCPsb coated with AntiA, 
AntiA embedded under PEM8, and AntiA embedded under CaP-PEM8 relative to their AntiA-
free controls (A). Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with 
CaP-PEM8 (blue) and AntiA embedded under CaP-PEM8 (red) for days 1, 3, and 5 (B). AntiA = 
213 μg/disk. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
Figure 2.7A 
ANOVA P value < 0.0001 
Tukey's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary 
AntiA vs. AntiA-PEM8 12.30 5.067 to 19.53 Yes ** 
AntiA vs. AntiA-CaP-PEM8 49.50 42.27 to 56.73 Yes **** 
AntiA-PEM8 vs. AntiA-
CaP-PEM8 
37.20 29.97 to 44.43 Yes **** 
Figure 2.7B 
Unpaired t test  
Day 1 P value 0.0152 
 
Day 3 P value 0.0029 
 
Day 5 P value 0.0008 
Emily Elizabeth Jacobs – University of Connecticut, 2016 
 
 49 
 
 
Figure 2.8 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with CaP-
PEM30 (blue) and Anti embedded under CaP-PEM30 (red) for days 1, 3, 5, and 7. AntiA = 213 
μg/disk. (* p < 0.05, ** p < 0.01). 
Unpaired t test  
Day 5 P value 0.0441 
Day 7 P value 0.0030 
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Figure 2.9 Day 1 % LIVE® stained area of MC3T3-E1s cultured on AntiA with no coating 
compared to its AntiA-free control, AntiA embedded under PEM30 compared to its AntiA-free 
control, and AntiA embedded under bCaP-PEM30 compared to its AntiA-free control (A), (**** 
p value < 0.0001). The calculated day 1 % cell deaths of AntiA, AntiA-PEM30, and AntiA-
bCaP-PEM30 relative to their AntiA-free controls (B), (* p value < 0.05, *** p value < 0.001, 
**** p value < 0.0001). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on 
TCPsb (C) vs. TCPsb coated with AntiA (D), PEM30 (E) vs. AntiA-PEM30 (F), and bCaP-
PEM30 (G) vs. AntiA-bCaP-PEM30 (H). Scale bar = 250 μm. 
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Figure 2.9A 
ANOVA P value < 0.0001 
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
TCPsb vs. TCPsb 
+ AntiA 
34.26 27.76 to 40.76 Yes **** 
PEM30 vs. PEM30 
+ AntiA 
14.84 7.894 to 21.79 Yes **** 
 
Figure 2.9B 
ANOVA P value < 0.0001 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant? Summary 
TCPsb+ AntiA vs. PEM30 
+ AntiA 
17.11 3.297 to 30.92 Yes * 
TCPsb+ AntiA vs. bCaP-
PEM30+ AntiA 
103.3 89.50 to 117.1 Yes **** 
PEM30+ AntiA vs. bCaP-
PEM30+ AntiA 
86.20 71.44 to 101.0 Yes **** 
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Figure 2.10 MC3T3-E1 FGF-2 dose response day 1 LIVE® staining. (* p < 0.05, ** p < 0.01, 
**** p < 0.0001). The 150 ng FGF-2 dose was selected to use for all studies. 
ANOVA P value < 0.0001 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of diff. Significant? Summary 
bCaP-PEM30 vs. bCaP-PEM30-FGF2 
(15 ng) 
-8.097 -12.74 to -3.452 Yes ** 
bCaP-PEM30 vs. bCaP-PEM30-FGF2 
(150 ng) 
-21.94 -26.58 to -17.30 Yes **** 
bCaP-PEM30-FGF2 (1.5 ng) vs. bCaP-
PEM30-FGF2 (15 ng) 
-4.779 -9.423 to -
0.1343 
Yes * 
bCaP-PEM30-FGF2 (1.5 ng) vs. bCaP-
PEM30-FGF2 (150 ng) 
-18.62 -23.27 to -13.98 Yes **** 
bCaP-PEM30-FGF2 (15 ng) vs. bCaP-
PEM30-FGF2 (150 ng) 
-13.84 -18.49 to -9.199 Yes **** 
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Figure 2.11 Schematic representation of Factor 1 (A) and Factor 2 (B) location within the bCaP-
PEM30 coating. The theoretical immediate, and delayed delivery profiles of Factor 1 (C) and 
Factor 2 (D) respectively. 
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Figure 2.12 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30-FGF2 (blue) and 
bCaP-PEM30 (green) for up to 5 days (A), (** p < 0.01, *** p < 0.001, **** p < 0.0001) (FGF-
2 = 150 ng/disk). Fluorescent images of day 1 LIVE® staining of MC3T3-E1s cultured on 
TCPsb coated with bCaP-PEM30-FGF2 (B) and bCaP-PEM30 (C). Scale bar = 250 μm.  
Unpaired t test  
Day 1 P value 0.0013 
Day 2 P value < 0.0001 
Day 3 P value < 0.0001 
Day 4 P value < 0.0001 
Day 5 P value 0.0003 
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Figure 2.13 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with bCaP-
PEM30 (green, -A/-F) and bCaP-PEM30-FGF2 (blue, -A/+F) at 4h (A), and day 1 (B), (** p < 
0.01).  Fluorescent images of LIVE® staining of MC3T3-E1s cultured on TCPsb coated with 
bCaP-PEM30 and bCaP-PEM30-FGF2 after 4 h (C, D) and 1 day (E, F). 
Unpaired t test  
Day 1 P value 0.0013 
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Figure 2.14 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30 (green) and AntiA-
bCaP-PEM30 (red) for up to 5 days (A), (* p < 0.05, ** p < 0.01, *** p < 0.001) (AntiA = 213 
μg/disk). Fluorescent images of day 3 LIVE® staining of MC3T3-E1s cultured on TCPsb coated 
with bCaP-PEM30 (B) and AntiA-bCaP-PEM30 (C). Scale bar = 250 μm.  
Unpaired t test  
Day 2 P value 0.0306 
Day 3 P value 0.0001 
Day 4 P value 0.0031 
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Figure 2.15 Percent LIVE® staining of MC3T3-E1s cultured in day 1- or day 3-release medium 
collected from bCaP-PEM30-FGF-2 (-A/+F, blue) or AntiA-bCaP-PEM30-FGF-2 (+A/+F, 
ornage) coated disks incubated at 37°C without cells, (FGF-2 = 150 ng/disk, AntiA = 213 
μg/disk). 
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Figure 2.16 Day 1 LIVE® stained area of MC3T3-E1s cultured on the FGF-2 groups (+F) 
compared to their FGF-2-free controls (-F) (FGF-2 = 150 ng/disk) (A), (*** p < 0.001, **** p < 
0.0001). Percent LIVE® stained area of MC3T3-E1 cells cultured on bCaP-PEM30-FGF2 (blue) 
and AntiA-bCaP-PEM30-FGF2 (orange) over time (B), (**** p < 0.0001). Fluorescent images 
of LIVE® staining of MC3T3-E1s cultured on bCaP-PEM30-FGF-2 (-A/+F), and AntiA-bCaP-
PEM30-FGF-2 (+A/+F), at time points 4 h, days 1-5 (C). Scale bar = 250 μm. 
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Figure 2.16A 
ANOVA P value < 0.0001 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of 
diff. 
Significan
t? 
Summa
ry 
bCaP-PEM30 vs. bCaP-PEM30-FGF2 -16.40 -22.65 to -
10.15 
Yes **** 
AntiA-bCaP-PEM30 vs. AntiA-bCaP-
PEM30-FGF2 
-11.89 -18.13 to -
5.637 
Yes *** 
 
Figure 2.16B 
Unpaired t test  
Day 3 P value < 0.0001 
Day 4 P value < 0.0001 
Day 5 P value < 0.0001 
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Figure 2.17 Schematic representation of “in and out” diffusion and exponential growth of 
hydrophilic polyelectrolytes during layer-by-layer build up of the PEM film (A). Resulting 
interlayer diffusion of multiple factors within the PEM layers (B) and theoretical co-delivery of 
factors (C).  
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Chapter 3 
Tunable Delivery Kinetics of Multiple Factors from Biomimetic Calcium Phosphate/PEM 
Coatings 
3.1 Introduction 
The ability to sequentially delivery multiple factors is an important feature of new biomaterials 
to stimulate successful tissue regeneration.  This is because natural healing and regeneration is 
tightly controlled by a cascade of growth factors and signaling molecules, that all act at specific 
times during development and repair [4]. Many biological systems need specific growth factor 
exposure on a time scale of days to weeks, so it is important that new biomaterials offer specific 
tunability so the delivery of growth factors from the material can best match the natural process, 
resulting in enhanced tissue regeneration.  For example, during bone fracture healing, the first 
stage of healing, acute inflammation, typically last around three days [38]; during this time 
monocytes, mesenchymal stem cells (MSCs), and subsequent osteoprogenitor cells are recruited 
to the defect site. For successful healing to occur, it is important that inflammation subside and 
these progenitor cells have a chance to proliferate and fill the defect before differentiating. Bone 
morphogenetic protein-2 (BMP-2) is considered one the key growth factors responsible for 
osteoprogenitor differentiation [36], and it has been shown that BMP-2 delivered too early can 
inhibit in vitro osteogenesis [104]. Therefore it is critical that this stage of fracture healing 
completes before delivering the differentiation agent from the biomaterial. 
 In the previous chapter, it was shown that the biomimetic calcium 
phosphate/polyelectrolyte multilayer coatings made with 30 bilayers of poly-L-Lysine/poly-L-
glutamic acid (bCaP-PEM30), could successfully sequentially delivery two factors in vitro to 
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osteoprogenitor cells, with access to the embedded factor occurring on day 3 of culture. It was 
also shown that the delivery of the factors was based on the cell-mediated degradation of the 
coating and not diffusion of the factors out. It is expected that the delivery kinetics in vivo would 
most likely be accelerated due to the presence of other cell-types, such as macrophages, that are 
known to be capable of rapid resorption of PLLys-PLGlut PEM materials [121].  This motivated 
the work of this chapter, which is focused on altering the PEM and bCaP portions of the bCaP-
PEM30 coating to further delay access to the embedded factor when cultured with 
osteoprogenitor cells.  The PEM component of the coating was altered by increasing the number 
of bilayers, shown to increase the degradation time of the film in vitro [114], and by using the D-
enantiomers of the polyelectrolytes, poly-D-Lysine and poly-D-Glutamic acid, also shown to 
slow the cellular degradation of the film [150].  The bCaP layer was altered by increasing time in 
the simulated body fluid solutions used to produce the layer [168], which is a demonstrated 
method for increasing the thickness of the bCaP layer [172]. In addition, because delivery of 
factors from the bCaP-PEM30 coating is cell-mediated, and monocytes/macrophages are one of 
the first cell-types that would interact with the coating in vivo [119], cellular assays were 
conducted with the mouse macrophage cell line, RAW 264.7, to determine the in vitro delivery 
kinetics of multiple factors from the bCaP-PEM30 coating. 
This chapter reports the in vitro cell culture assessment of the sequential delivery kinetics 
of two factors with opposing activity (proliferative vs. cytotoxic) delivered from bCaP-PEM 
coatings with alternations made to the PEM portion of the coating, or to the bCaP layer of the 
coating. In addition, changes in factor delivery kinetics resulting from changing the cell type 
interacting with the coating, were used to investigate the cell-mediated degradation of the 
coating. MC3T3-E1 mouse osteoprogenitor cells and RAW 264.7 mouse macrophage cells were 
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used for the cell culture evaluation assays because they provide important information about the 
potential response of host progenitor cells (MC3T3-E1) and immune response (RAW 264.7) to 
implanted materials coated with bCaP-PEM. 
3.2 Materials and Methods 
3.2.1 Factor Application 
To demonstrate delivery kinetics from the bCaP-PEM coatings, a combination of a proliferative 
factor, recombinant human fibroblast growth factor-2 (FGF-2) (150 ng/disk) (R & D Systems, 
Minneapolis, MN), and a model cytotoxic agent antimycin A (AntiA) (213 μg/disk) (Sigma, St. 
Louis, MO) was used.  It was expected that the FGF-2 would immediately stimulate cellular 
proliferation, and then at a later time point the cells would access the AntiA and die, indicating 
successful bio-active delivery of the factors from the coating. Prior to coating application, 10 μl 
of 40mM antimycin A in ethanol (213 μg/disk) was adsorbed onto the sandblasted plastic surface 
and was allowed to completely dry to maximize binding. The disks were rinsed 3x with saline 
before coating application.  During the coating application the disks were protected from light 
because AntiA is light sensitive. After AntiA adsorption, and coating application, 375 ng/ml 
FGF-2 in saline was allowed to adsorb to the coated disks for 1hr, then rinsed 3x with saline.  
Enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN) testing was 
performed and determined approximately 80% FGF-2 binds, (actual adsorbed dose ~120 
ng/disk).  
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3.2.2 Tuning bCaP-PEM30 Delivery Kinetics 
3.2.2.a Increasing Number of PEM Bilayers 
AntiA (213 μg/disk) was adsorbed and bCaP was applied as previously described in Ch. 2.  102 
bilayers of PEM were applied (PLLys-PLGlut = 1 bilayer).  This dip-coating process was 
automated with the use of a histology-staining machine (Varistain 24-4, Thermo Shandon, 
Loughborough, UK) and custom designed sample holders.  All polyelectrolyte solutions and 
saline rinses were replaced every 30 bilayers. After PEM102 application, disks were UV-
sterilized on both sides.  FGF-2 (150 ng/disk) was adsorbed as previously described. The 
sequential delivery group (AntiA-bCaP-PEM102-FGF2) and its AntiA-free control (bCaP-
PEM102-FGF2) were each tested only once to evaluate the feasibility of this approach towards 
tuning delivery kinetics, and the results should be considered for pilot purposes only. 
3.2.2.b Use of “D” Enantiomers 
AntiA (213 μg/disk) was adsorbed and bCaP was applied as previously described in Ch. 2.  30 
bilayers of PEM were applied by alternate 10 min dippings into 1 mg/ml poly-D-Glutamic acid 
(PDGlut-) or poly-D-Lysine (PDLys+) solutions (Sigma, St. Louis, MO), with seven saline 
rinses between each. After PEMD30 application, disks were UV-sterilized on both sides.  FGF-2 
(150 ng/disk) was adsorbed as previously described. The sequential delivery group (AntiA-
bCaP-PEMD30-FGF2) and its AntiA-free control (bCaP- PEMD30-FGF2) were each tested only 
once to evaluate the feasibility of this approach towards tuning delivery kinetics, and the results 
should be considered for pilot purposes only.  
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3.2.2.c Adjusting Time in Solution B to Change bCaP Layer Thickness 
AntiA (213 μg/disk) was adsorbed as previously described.  During bCaP deposition, Solution A 
was applied as normal, (~24 h at 37°C); time in Solution B was either increased or decreased 
from the normal ~24 h at 50°C.  Increased times were extended to 48 h (bCaP(48)) in Solution B, 
decreased times were dropped to 7 h (bCaP(7)) in Solution B. After bCaP(7) or bCaP(48) were 
deposited, PEM30 and FGF-2 (150 ng/disk) were applied as previously described in Ch. 2. The 
sequential delivery group using 7 h in Solution B (AntiA-bCaP(7)-PEM30-FGF2) was tested 
only once to evaluate the feasibility of this approach towards tuning delivery kinetics, and the 
results should be considered for pilot purposes only. The sequential delivery group (AntiA-
bCaP(48)-PEM30-FGF2) and its AntiA-free control (bCaP(48)-PEM30-FGF2) prepared using 
48 h in Solution B were each tested at least two times. 
 bCaP(7) and bCaP(48) coated disks were examined to characterize surface morphology 
and consistency. The microscopic morphology was characterized using SEM (JSM - 5900LV, 
Jeol USA Inc. Peabody, MA). Disks were cut in half, allowing examination of the coating cross-
section and measurement of the coating thickness with SEM. 
3.2.2.d MC3T3-E1 Assays for Assessing Delivery Kinetics 
MC3T3-E1 mouse calvarial osteoprogenitor cells (ATCC, Manassas, VA) were cultured in 
alpha-Minimal Essential Medium (α-MEM, No. 12571, Gibco BRL, Invitrogen), supplemented 
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate.  
Cells were maintained and prepared for cell-culture assays as previously described in Ch. 2. 
The coated disks were placed into 12-well tissue culture plates and submerged in α-MEM 
medium for 30-45 min. MC3T3-E1s were seeded at 4 x 104 cells/cm2 in culture medium and 
were incubated at 37°C and 5% CO2 for 4h, 1, 2, 3, 4, 5, 6, and 7 days, (medium changed on day 
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3 and 6).  LIVE® staining and ImageJ analyses were performed to determine a measure of cell 
number as previously described in Ch. 2.  
3.2.3 RAW 264.7 Assays for Evaluation of bCaP-PEM30 Delivery Kinetics 
3.2.3.a Preparation of bCaP-PEM30 disks 
Biomimetic calcium phosphate (bCaP) and poly-l-Lysine/poly-l-Glutamic acid PEM coatings 
(bCaP-PEM30) were prepared on sandblasted tissue culture plastic disks (TCPsb) as described in 
Ch. 2. AntiA (213 μg/disk), bCaP-PEM30, and FGF-2 (150 ng/disk) were applied as previously 
described (AntiA-bCaP-PEM30-FGF2). Control coated disks were also prepared (bCaP-PEM30-
FGF2, bCaP-PEM30, AntiA-bCaP-PEM30). 
3.2.3.b RAW 264.7 Assays for Assessing Delivery Kinetics 
RAW 264.7 mouse monocyte macrophage cells (ATCC, Manassas, VA) were cultured in 
DMEM high glucose, pyruvate medium, (No. 11995, Gibco BRL, Invitrogen), supplemented 
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate. 
Medium was refreshed every 2–3 days until 70-80% confluent and split at a ratio of 1:8. 
Passages 10–30 were routinely used. The cells were detached from tissue culture dishes by use of 
a cell-scraper. Cells were counted using an automated cell counter (Bio-Rad, TC20) with trypan 
blue staining to assess cell number and viability prior to the cell proliferation assays. 
The coated disks were sterilized prior to cell culture by exposure to UV light for 10 min 
to each side of the disks.  They were then placed into 12-well treated tissue culture plates 
(Corning Inc., Corning, NY) and submerged in α-MEM medium for 30-45 min. RAW 264.7s 
were seeded at 7.9 x 103 or 3 x 104 cells/cm2 in culture medium and were incubated at 37°C and 
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5% CO2 for up to 3 days. LIVE® staining and ImageJ analyses were performed as previously 
described in Ch. 2.  All groups reported for each cell seeding density were performed twice. 
3.2.3 Statistical Analyses 
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey 
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations 
are shown in all figures. 
3.3 Results 
3.3.1 Tuning bCaP-PEM30 Delivery Kinetics 
3.3.1.a Increasing Number of PEM Bilayers 
MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2 resulted in a significant decrease in 
LIVE® staining on day 3 compared to its AntiA-free control (bCaP-PEM102-FGF2), (Fig. 
3.1A), (* p < 0.05). LIVE® staining of MC3T3-E1s cultured on the control bCaP-PEM30-FGF2 
disks were significantly higher on days 3 and 5 as compared to cells on bCaP-PEM102-FGF2 
disks, (Fig. 3.1B), (*** p < 0.001). Significant difference in LIVE® staining were observed 
between MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 disks and AntiA-bCaP-
PEM102-FGF2 disks on days 3 and 5, (Fig 3.1C), (* p < 0.05, ** p < 0.01).  
3.3.1.b Use of “D” Enantiomers 
MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2 resulted in a significant decrease in 
LIVE® staining on day 3 compared to its AntiA-free control (bCaP-PEMD30-FGF2), (Fig. 
3.2A), (**** p < 0.0001). LIVE® staining of MC3T3-E1s cultured on the control bCaP-PEM30-
FGF2 disks were significantly higher on days 3 and 5 as compared to cells on bCaP-PEMD30-
FGF2 disks, (Fig. 3.2B), (* p < 0.05, ** p < 0.01). Significant difference in LIVE® staining 
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were observed between MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 disks 
and AntiA-bCaP-PEMD30-FGF2 disks on day 5, (Fig. 3.2C), (* p < 0.05). 
3.3.1.c Adjusting Time in Solution B to Change bCaP Layer Thickness 
Schematic representations of bCaP-PEM30 made with bCaP after 7 h in Solution B (bCaP(7)), 
after 24 h in Solution B (the normal bCaP procedure, bCaP(24)), and after 48 h in Solution B 
(bCaP(48)) are illustrated in Fig. 3.3. Scanning electron microscopy revealed that all bCaPs 
produced formed densely packed, nano-crystals, (Fig. 3.4).  bCaP(7), bCaP(24), and bCaP(48) 
resulted in coating thicknesses of 1.8 + 0.7 μm, 5.8 + 1.8 μm, and 24.0 + 2.4 μm respectively. 
Culturing MC3T3-E1s on AntiA-bCaP(7)-PEM30-FGF2 resulted in similar % LIVE® stained 
area as culturing the cells on AntiA-bCaP(24)-PEM30-FGF2, however culturing the cells on 
AntiA-bCaP(48)-PEM30-FGF2 resulted in a significant increase in LIVE® staining on day 3 as 
compared to the other two groups (Fig. 3.5). Culturing MC3T3-E1s on AntiA-bCaP(48)-PEM30-
FGF2 resulted in a significant decrease in percent LIVE® stained area on day 3 and throughout 
the remaining time points in the study as compared to cells cultured on its AntiA-free control 
(bCaP(48)-PEM30-FGF2) (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001), (Fig. 3.6), 
therefore AntiA was still being initially accessed on day 3; however unlike cells cultured on 
AntiA-bCaP(24)-PEM30-FGF2 where after day 3 the cells start to recover (Fig. 3.6A,B), cells on 
AntiA-bCaP(48)-PEM30-FGF2 continue to decrease from day 3 through day 7 (Fig. 3.6C,D).  It 
should be noted that the data obtained for days 5-7 came from a separate study than the one that 
produced data for time points 4h, days 1-4; this is because the number of disks that can be 
produced at once is limited and can only provide enough replicates for a maximum of 5 time 
points. Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24)-PEM30 and bCaP(48)-
PEM30 are illustrated in Fig. 3.7. 
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3.3.2 RAW 264.7 Assays for Evaluation of bCaP-PEM30 Delivery Kinetics 
Increasing the RAW 264.7 seeding density from 7.9k to 30k cells/cm2 significantly increased 
percent LIVE® stained area within 4 hours of culture and throughout all time points of the study 
when cultured on bCaP-PEM30-FGF2 (Fig.3.8A). Increasing the RAW 264.7 seeding density 
from 7.9k to 30k cells/cm2 significantly decreased percent LIVE® stained area within 4 hours of 
culture and throughout all time points of the study when cultured on AntiA-bCaP-PEM30-FGF2 
(Fig.3.8B). This indicates that AntiA is being accessed immediately when RAW cells are seeded 
at 30k cells/cm2. At the lower seeding density, no differences between cells cultured on bCaP-
PEM30-FGF2 and AntiA-bCaP-PEM30-FGF2 were observed at 4 h, day 1, or day 2 (Fig.3.9) 
indicating the AntiA is not being accessed at these time points. However, at the higher seeding 
density, a significant decrease in LIVE® staining was observed on the AntiA-bCaP-PEM30-
FGF2 group compared to its AntiA-free control at 4 h and throughout the duration of the study 
(Fig. 3.10); this indicates that sequential delivery is no longer occurring because there is no 
delayed access to the embedded AntiA. A significant increase in percent LIVE® stained area 
after 4 h of culture for RAW cells seeded at 30k cells/cm2 on bCaP-PEM30-FGF2 (blue, -A/+F) 
was observed as compared to bCaP-PEM30 (green, -A/-F, ** p < 0.01) and AntiA-bCaP-
PEM30-FGF2 (orange, +A/+F, *** p < 0.001), (Fig. 3.11A); Addition of FGF-2 to bCaP-
PEM30 stimulated initial RAW cell attachment and proliferation within 4 h. Addition of FGF-2 
to AntiA-bCaP-PEM30 (orange) resulted in significant decreases in RAW cell LIVE® stained 
area at 4 h, and days 1-3 as compared to the FGF-2-free control (red), (* p < 0.05, ** p < 0.01), 
(Fig. 3.11 B).   
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3.4 Discussion 
The ability to control the timing and rate of delivery of factors from a biomaterial is of critical 
importance for the success of the biomaterial when its aim is to replicate a natural biological 
process. In this study the use of a novel biomimetic calcium phosphate/polyelectrolyte multilayer 
coating was used to demonstrate tunable delivery kinetics of multiple biologically active factors. 
In vitro cell culture studies were used to demonstrate cell-mediated, sequential delivery of a 
proliferative factor (FGF-2) and a cytotoxic factor (AntiA) from the bCaP-PEM30 coating with 
alterations made to the bCaP thickness or the PEM composition.  Change of delivery kinetics due 
to change in cell type from pre-osteoblast progenitor to monocyte/macrophage was also 
demonstrated. 
The first attempt at increasing time of access to the embedded factor was to increase the 
number of PEM bilayers from 30 to 102. Increasing the number of PEM layers has been shown 
to increase the thickness of the film and time to degrade the film [114]. Increasing the number of 
PLLys-PLGlut bilayers resulted in AntiA still being accessed on day 3 (Fig. 3.1A), and no 
significant change in MC3T3-E1 proliferation with time when cultured on bCaP-PEM102-FGF2, 
(Fig. 3.1B). The inability of the cells to grow on the coating without AntiA could be due to 
inhibited burst delivery of FGF-2 or the increased concentration of poly-L-Lysine within the 
coating. PLLys is known to be cytotoxic [116, 117], and it is believed that increasing the number 
of PEM bilayers exceeded a tolerable level of PLLys for the MC3T3-E1 cells; therefore this is 
not a viable strategy for improving the sequential delivery profile. 
The next attempt to increase the amount of time to access the embedded factor was to use 
the D-enantiomers of the polyelectrolytes, poly-D-Lysine and poly-D-Glutamic acid. Other 
groups have attempted tuning cellular access of protein in the same 30-bilayer PEM system by 
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increasing the ratio of D- to L-enantiomer polyelectrolytes within the film (shown to slow the 
cellular degradation of the film); this resulted in delayed access to the protein for an additional 6 
h [150].  In the present study, AntiA access was still being observed on day 3 (Fig. 3.2A); this is 
most likely due to the very short-term (hours) tune-ability of the D-enantiomer approach. Again, 
the cells observed slight inhibited growth on bCaP-PEMD30-FGF2 as compared to the bCaP-
PEM30-FGF2 control (Fig. 3.2B). Though the D-enantiomer approach did not significantly 
changed access kinetics to the AntiA, it did appear to inhibit the delivery kinetics of the FGF-2. 
Not surprisingly, altering the composition or number of PEM bilayers within the coating 
only seemed to change the delivery kinetics of the FGF-2, which is adsorbed into the PEM 
layers. Another strategy to delay release of an embedded factor commonly employed with PEM 
systems is to covalently cross-link the polyelectrolytes. Wood et al. showed a delay up to 25 h of 
release of an embedded factor with the use of a single thermally cross-linked poly(allylamine 
hydrochloride)(PAH)/poly(acrylic acid) (PAA) layer; however the cross-linking procedure 
required the material to be heated to 215°C for 20 min which would denature most biological 
agents [154]. Hsu et al. showed similar results by cross-linking chitosan/poly(b-l-malic acid) via 
copper-free click chemistry, and could delay release of an embedded factor up to 24 h [187]. 
Many biological systems need specific growth factor exposure on a time scale of days to weeks, 
not hours, therefore these short-term tuning strategies (increasing PEM bilayers, using D-
enantiomers) are not sufficient for delaying access to the embedded factor nor for in vivo 
purposes.   
The final attempt at tuning the delivery kinetics of the embedded factor was to increase 
the thickness of the bCaP layer by altering the time the samples spent in Solution B of the SBF 
CaP method during bCaP deposition in the bCaP-PEM30 procedure.  As the literature suggested 
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[118, 172-174], increasing or decreasing this time resulted in an increase or decrease in the bCaP 
layer thickness (Fig. 3.4). Depositing a thinner bCaP(7) coating resulted in similar delivery 
kinetics of the embedded AntiA as using the normal bCaP(24) layer (Fig. 3.5). Depositing a 
thicker bCaP(48) layer resulted in a significant increase in LIVE® staining on day 3 as compared 
to bCaP(7) and bCaP(24) (Fig. 3.5). Culturing MC3T3-E1s on AntiA-bCaP(48)-PEM30-FGF2 
resulted in a significant decrease in percent LIVE® stained area on day 3 and throughout the 
remaining time points in the study as compared to cells cultured on its AntiA-free control 
(bCaP(48)-PEM30-FGF2) (Fig. 3.6); therefore AntiA was still being initially accessed on day 3; 
however unlike cells cultured on AntiA-bCaP(24)-PEM30-FGF2 where after day 3 the cells start 
to recover (Fig. 3.6A,B), cells on AntiA-bCaP(48)-PEM30-FGF2 continue to decrease from day 
3 through day 7 (Fig. 3.6C,D). It is hypothesized that increasing the bCaP layer thickness 
changed the AntiA delivery from burst (observed with bCaP(24)) to potential sustained delivery 
(with bCaP(48)), hence why the cells continue to die over the course of multiple days. These 
theoretical delivery profiles of FGF-2 and AntiA from bCaP(24)-PEM30 and bCaP(48)-PEM30 
are illustrated in Fig. 3.7. 
It was shown in chapter 2 that the bCaP-PEM30 coating delivery of factors is cell-
mediated as indicated by the lack of proliferative or cytotoxic effects observed when cells were 
cultured with collected release medium (from coated disks incubated without cells) (Fig. 2.15). 
These results lead to the hypothesis that using a cell-type more capable of degradation or 
resorption would result in faster delivery kinetics of the embedded factor.  Because monocytes 
are one of the first cells recruited to the area when tissue is damaged or infected [119], these cells 
may be some of the first to interact with the bCaP-PEM30 coating in vivo. RAW 264.7 mouse 
monocyte macrophage cells (RAW) were therefore chosen for evaluating sequential delivery 
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kinetics of the bCaP-PEM coatings as a comparison to the pre-osteoblast MC3T3-E1 cells that 
are present at slightly later stages in the bone repair process. Two different RAW cell densities 
were tested on the bCaP-PEM30 coatings, 7.9k and 30k cells/cm2. As expected, the increased 
cell seeding density resulted in increased LIVE® staining within 4 h on the control coatings 
(bCaP-PEM30-FGF2, no AntiA, Fig. 3.8A).  Surprisingly, the increased cell seeding density did 
not increase 4 h LIVE® staining of RAW cells cultured on AntiA-bCaP-PEM30-FGF2 coatings 
(Fig. 3.8B); in fact it resulted in a significant decrease in LIVE® staining, suggesting the RAW 
cells may be accessing the AntiA within the first 4 h of culture.  When the RAW cells are seeded 
at lower density (7.9k cells/cm2), no differences in LIVE® staining are observed between the 
AntiA group and the AntiA-free control at the 4 h, day 1 and day 2 time points (Fig. 3.9); 
indicating AntiA is being blocked until access on day 3, similar to the osteoprogenitor cells. 
However, when the seeding density is increased to 30k cells/cm2, a significant decrease in 
LIVE® staining is observed at the 4 h time point when comparing the AntiA group to its AntiA-
free control (Fig. 3.10).  This is much faster AntiA access than the day 3 access observed for the 
MC3T3-E1s cultured on the same coating, and as a result suggests that the bCaP-PEM30 coating 
can only provide co-delivery to macrophages at this density, as compared to the desired 
sequential delivery observed with the osteoprogenitors (Fig. 3.12). These results demonstrate that 
not only is the type of cells interacting with the coating important, but the number of cells as 
well; increasing the cell number resulted in faster degradation of the coating. 
The two seeding densities selected to be used in the present studies were chosen to 
possibly mimic a normal, acute inflammation response (lower seeding density), as compared to a 
more severe, chronic inflammation response that could lead to a foreign body reaction (higher 
seeding density).  The progression of events in inflammation and the foreign body response to an 
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implanted biomaterial requires the migration of monocytes/macrophages to the implant site 
(acute inflammation) and then the further propagation of chemoattractive signals such as PDGF, 
TNF-α, IL-6, granulocyte colony-stimulating factor (GCSF), and macrophage colony stimulating 
factor (MCSF) to call more macrophages to the wound site leading to chronic inflammation 
[188, 189].  At the lower seeding density, a 3 day delay to the embedded AntiA was occurring 
suggesting that a normal acute inflammatory response during the bone fracture healing process 
would offer some delay to the embedded factor in vivo.  The higher seeding density that may 
associate to more severe, chronic inflammation response to the implanted biomaterial, offered no 
delay to the embedded AntiA meaning a severe reaction to the bCaP-PEM30 coating in vivo, 
would not be able to provide sequential delivery.  Though our goals in vivo are to influence the 
osteoprogenitor cells with growth factor delivery, it is important to consider the effects of 
inflammation, therefore monocyte/macrophage cells, on the coating degradation and ultimate 
timing of growth factor delivery. A better understanding of cell type and number delivery 
kinetics of the bCaP-PEM coating would help better predict in vivo delivery kinetics. 
Macrophages are capable of degrading non-cross-linked polyelectrolyte multilayer films 
[122]; more specifically, RAW 264.7 cells have previously been shown to digest PLLys-PLGlut 
multilayer particles [121], therefore it was expected that the RAW cells could degrade the PEM 
portion of the bCaP-PEM coating. Similar to the MC3T3-E1 osteoprogenitor cells, the RAW 
cells cannot dissolve or resorb the bCaP layer when in their undifferentiated state, as used in the 
present studies, (not differentiated into osteoclasts) [190]. It is therefore speculated that the rapid 
access to the embedded AntiA when the macrophages are seeded at the higher density is the 
result of their ability to degrade the PEM layers faster than the osteoprogenitors. Similar to the 
MC3T3-E1s, it is predicted that the RAW cells access the AntiA by being able to migrate 
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through micro-cracks in the bCaP layer to access the AntiA. FGF-2 has been shown to stimulate 
macrophage recruitment [191]; Fig. 3.11A shows that addition of FGF-2 to bCaP-PEM30 
without AntiA causes a significant increase in initial cell attachment (4h, blue vs. green); 
however, when AntiA is present in the coating, addition of FGF-2 causes a significant decrease 
in LIVE® staining at the 4 h time point (Fig. 3.11B).  These results indicate that FGF-2 is 
increasing initial cell attachment and that the increase in cells increases coating degradation as 
compared to the FGF-2-free control (Fig. 3.11B). 
3.5 Conclusions 
The bCaP-PEM coating is capable of local, cell-mediated delivery to both osteoprogenitor cells 
and macrophages. This means that the bCaP-PEM coating has the potential provide controlled, 
local delivery of growth factors in vivo, at the early stages of bone fracture healing. Increasing 
the number of PEM bilayers (30 to 102) within the coating could not further delay 
osteoprogenitor access to the embedded AntiA, but potentially inhibited the delivery kinetics of 
the FGF-2. Changing the chemical composition of the polyelectrolytes (L- to D- enantiomers) 
also could not further delay osteoprogenitor access to the embedded AntiA, but did hinder the 
delivery kinetics of the FGF-2.  Increasing the thickness of the bCaP coating (~24 μm) from the 
normal ~6 μm did not change the initial timing of access to the embedded AntiA, but did change 
the delivery of AntiA from burst to sustained delivery over the course of 4 days to the 
osteoprogenitor cells.  Changing the cell type used to evaluate delivery kinetics from the coating 
from osteoprogenitors to macrophages significantly increased access time to the embedded 
factor.  When the macrophages were seeded at a low density (7.9k cells/cm2) the bCaP-PEM30 
coating provided 3 days delayed access to the embedded factor, similar to the osteoprogenitors. 
When the macrophages were seeded at a high density (30k cells/cm2) the bCaP-PEM30 coating 
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failed to provide any delayed access to the embedded factor.  These results highlight the 
importance of cell type and number when evaluating delivery kinetics from a cell-mediated 
delivery system. Understanding the macrophage response prior to the osteoprogenitor interaction 
with bCaP-PEM30 will better predict the in vivo response to the implanted bCaP-PEM30 coated 
scaffold. 
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Figure 3.1 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2 
(orange checker) as compared to cells cultured on bCaP-PEM102-FGF2 (blue checker) on days 
1, 3, and 5 (A), (* p < 0.05). Percent LIVE® stained area of MC3T3-E1s cultured on the control 
bCaP-PEM30-FGF2 as compared to cells on bCaP-PEM102-FGF2, (B), (*** p < 0.001). 
Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 
as compared to cells on AntiA-bCaP-PEM102-FGF2, (C), (* p < 0.05, ** p < 0.01). AntiA = 
213 μg/disk, FGF-2 = 150 ng/disk. 
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Figure 3.1A 
Unpaired t test  
Day 3 P value 0.0202 
 
Figure 3.1B 
Unpaired t test  
Day 3 P value 0.0003 
Day 5 P value 0.0004 
 
Figure 3.1C 
Unpaired t test  
Day 3 P value 0.0003 
Day 5 P value 0.0004 
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Figure 3.2 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2 
(orange stripes) as compared to cells cultured on bCaP-PEMD30-FGF2 (blue stripes) on days 1, 
3, and 5 (A), (**** p < 0.0001). Percent LIVE® stained area of MC3T3-E1s cultured on the 
control bCaP-PEM30-FGF2 as compared to cells on bCaP-PEMD30-FGF2, (B), (* p < 0.05, ** 
p < 0.01). Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-
PEM30-FGF2 as compared to AntiA-bCaP-PEMD30-FGF2, (C), (* p < 0.05). AntiA = 213 
μg/disk, FGF-2 = 150 ng/disk. 
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Figure 3.2A 
Unpaired t test  
Day 3 P value < 0.0001 
 
Figure 3.2B 
Unpaired t test  
Day 3 P value 0.0100 
Day 5 P value 0.0360 
 
Figure 3.2C 
Unpaired t test  
Day 5 P value 0.0319 
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Figure 3.3 Schematic representations of bCaP-PEM30 coatings made with bCaP prepared by 7 h 
in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B (C). 
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Figure 3.4 Scanning electron microscopy images of the surface morphology and cross-section of 
bCaP prepared by 7 h in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B 
(C). bCaP(7) thickness = 1.8 + 0.7 μm, bCaP(24) thickness = 5.8 + 1.8 μm, and bCaP(48) 
thickness = 24.0 + 2.4 μm.  
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Figure 3.5 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP(7)-PEM30-
FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 on time points 4 h, 
days 1-4 (A), (** p < 0.01). Fluorescent images of MC3T3-E1s cultured on AntiA-bCaP(7)-
PEM30-FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 (B). AntiA 
= 213 μg/disk, FGF-2 = 150 ng/disk. 
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ANOVA P value = 0.0014 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of 
diff. 
Signific
ant? 
Summ
ary 
AntiA-bCaP(7h)-PEM30-FGF2 vs. AntiA-
bCaP(48h)-PEM30-FGF2 
-12.92 -20.32 to -
5.528 
Yes ** 
AntiA-bCaP(24h)-PEM30-FGF2 vs. AntiA-
bCaP(48h)-PEM30-FGF2 
-13.31 -20.22 to -
6.390 
Yes ** 
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Figure 3.6 Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(24)-PEM30-FGF2 (-
A/+F) and AntiA-bCaP(24)-PEM30-FGF2 (+A/+F) (A) with corresponding fluorescent images 
of cells (B), (**** p < 0.0001). (Note, this data is from Fig. 3.3 and is being shown for 
reference). Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(48)-PEM30-FGF2 (-
A/+F) and AntiA-bCaP(48)-PEM30-FGF2 (+A/+F) (C) with corresponding fluorescent images 
of cells (D), (* p < 0.05, ** p < 0.01*** p < 0.001, **** p < 0.0001). (Note, data obtain for 
Days 5, 6 and 7 were obtained from a separate experiment). Scale bar = 250 μm. AntiA = 213 
μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.6 A, see Figure 2.16B statistics 
Figure 3.6B 
Unpaired t test  
Day 3 P value 0.0304 
Day 4 P value 0.0037 
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Day 5 P value < 0.0001 
Day 6 P value < 0.0001 
Day 7 P value < 0.0001 
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Figure 3.7 Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24h)-PEM30 
demonstrating burst delivery of AntiA (A) and bCaP(48h)-PEM30 demonstrating sustained 
delivery of AntiA (B).  
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Figure 3.8 Percent LIVE® stained area of RAW 264.7 s cultured on bCaP-PEM30-FGF2 (-
A/+F) (A), and AntiA-bCaP-PEM30-FGF2 (+A/+F) (B) at seeding densities of 7.9k or 30k 
cells/cm2 (* p < 0.05, ** p < 0.01).  Fluorescent images of the cells at 4 h of culture (C). Scale 
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
Figure 3.8A 
Unpaired t test  
4 h P value 0.0084 
Day 1 P value 0.0118 
Day 3 P value 0.0141 
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Figure 3.8B 
Unpaired t test  
4 h P value 0.0146 
Day 1 P value 0.0023 
Day 3 P value 0.0162 
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Figure 3.9 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (-
A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 7.9k cells/cm2 (A), (* p < 0.05).  
Fluorescent images of the cells at 4 h, 1 day, 2 days and 3 days of culture (B). Scale bar = 250 
μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
Unpaired t test  
Day 1 P value 0.0211 
Day 3 P value 0.0380 
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Figure 3.10 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (-
A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 30k cells/cm2 (A), (* p < 0.05, ** p < 
0.01, *** p < 0.001).  Fluorescent images of the cells at 4 h, 1, 2, and 3 days of culture (B). Scale 
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk. 
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Unpaired t test  
4 h P value 0.0231 
Day 1 P value 0.0002 
Day 2 P value 0.0003 
Day 3 P value 0.0056 
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Figure 3.11 Percent LIVE® stained area of RAW 264.7 cells seeded at 30k cells/cm2 on bCaP-
PEM30 (green, -A/+F), bCaP-PEM30-FGF2 (blue, -A/+F), AntiA-bCaP-PEM30 (red, +A/-F), 
and AntiA-bCaP-PEM30-FGF2 (orange, +A/+F) at 4 h of culture, (A). Percent LIVE® stained 
area of RAW 264.7s seeded at 30k cells/cm2 on AntiA-bCaP-PEM30 (red), and AntiA-bCaP-
PEM30-FGF2 (orange) at 4 h, and days 1-3, (B). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001). AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.  
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Figure 3.11A 
ANOVA P value = 0.0002 
 
Figure 3.11B 
Unpaired t test  
4 h P value 0.0346 
Day 1 P value 0.0060 
Day 2 P value 0.0019 
Day 3 P value < 0.0001 
 
 
 
 
 
 
 
 
 
  
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary 
-A/-F vs. -A/+F -2.458 -3.651 to -1.265 Yes ** 
-A/+F vs. +A/+F 3.307 2.113 to 4.500 Yes *** 
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Figure 3.12 The theoretical sequential delivery profile of FGF-2 and AntiA from bCaP-PEM30 
cultured with osteoprogenitor cells (MC3T3-E1s at 40k cell/cm2) (A), as compared to the co-
delivery of factors from bCaP-PEM30 cultured with macrophages (RAW 264.7a at 30k 
cells/cm2) (B).  
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Chapter 4 
Sequential Delivery of FGF-2 and BMP-2 from Biomimetic Calcium Phosphate/PEM Coatings 
for In Vivo Osteogenesis 
4.1 Introduction 
Roughly 6.8 million patients each year seek medical attention in the United States for bone 
fractures (American Academy of Orthopaedic Surgeons). With modern treatment methods, most 
bone fractures heal without any problems. However, a small, but significant proportion of broken 
bones do not heal even with the best surgical or non-surgical treatments and this can lead to a 
delayed- or non-union. Several factors can increase the risk of failed bone fracture healing 
including: complicated/severe breaks, older age, poor nutrition, smoking, infection, and diseases 
such as anemia, osteoporosis, vitamin D deficiencies, and diabetes, (American Academy of 
Orthopaedic Surgeons). Treatment methods for large nonunions include the use of bone grafts or 
bone graft substitutes. Autogenous and allogenic bone grafts have desirable osteoconductive and 
osteoinductive properties, with autografts being considered the gold standard for treating these 
types of defects [192, 193]. These methods provide scaffolding for patient’s bone to heal across 
the nonunion/defect but lack the chemical signals and growth factors normally present to 
stimulate natural bone regeneration and can result in insufficient healing, especially when the 
autograft is taken from a patient with the increased risk factors that result in poor healing to 
begin with. 
There are a number of growth factors involved in bone healing, however bone 
morphogenetic protein-2 (BMP-2) is the main one used clinically for bone repair.  This is 
because BMP-2 is one of the main growth factors responsible for initiating the differentiation of 
Emily Elizabeth Jacobs – University of Connecticut, 2016 
 
 97 
osteoprogenitors into osteoblasts leading to new bone formation [36].  BMP-2 delivered via a 
collagen sponge (INFUSE Bone Graft, Medtronic, FDA approved) significantly enhances bone 
formation and successful spinal fusion, [28]; however its use has been limited due to 
complications with the required high dose of BMP-2 necessary for adequate bone formation.  
These complications include severe inflammation, ectopic bone formation, osteolysis, seroma 
formation, and possible increase in the risk of malignancy, [19, 30].  These problems stem from 
the collagen sponge’s inability to contain the supraphysiologic dose of BMP-2 in the local tissue 
environment and control its release. There is a need to refine the delivery and improve the 
efficacy of BMP-2 so that it can be locally delivered in lower doses, with less risk of 
complications.  
Another growth factor necessary for bone healing, fibroblast growth factor 2 (FGF-2), 
has been shown to increase proliferation, migration, and bone morphogenetic protein 2 (BMP-2) 
sensitivity of osteoprogenitor cells when delivered at early time points [36, 78], and to inhibit 
osteoblast differentiation at later stages [88]. The synergistic combination of FGF-2 with BMP-2 
has shown promise as a means to reduce the BMP-2 dose necessary for bone formation [93, 97]. 
Growth factors have different effects on natural bone regeneration depending on the 
developmental stage of the fracture healing process they are present during; therefore, sequence 
of delivery is important to optimize growth factor activity and healing. Too much and/or late 
stage exposure of FGF-2 at the same time as BMP-2 has been shown to reduce the amount of in 
vitro and in vivo bone formation [90, 93, 194].  BMP-2 delivered too early can also inhibit in 
vitro osteogenesis [104]. The benefit of sequential delivery of FGF-2 (early) and BMP-2 (late) 
has been further shown through growth factor spiking during in vitro osteogenesis studies [88, 
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90], providing additional motivation for the development of biomaterial systems for sequential 
delivery.  
 This chapter focuses on the use of a biomimetic calcium phosphate, poly-L-Lysine/poly-
L-Glutamic acid (bCaP-PEM) coating applied to the commercially available bone graft substitute 
Healos® (DePuy Synthes Spine, Raynham, MA) to sequentially deliver FGF-2 and BMP-2 in a 
mouse calvarial defect model.  It is hypothesized that early delivery of FGF-2 will stimulate the 
proliferation of osteoprogenitor cells, and delayed delivery of BMP-2 will stimulate the 
osteoprogenitor cells to differentiate into functioning osteoblasts, and this sequential delivery 
profile will enhance in vivo BMP-2 stimulated bone formation. 
4.2 Materials and Methods 
4.2.1 Design of Sequential Delivery System 
For all in vivo testing a calcium phosphate layer was precipitated prior to a PLLys-PLGlut PEM 
application for delivery of BMP-2 only (Fig. 4.1A) or BMP-2and FGF-2 (Fig. 4.2B). The 
theoretical delivery profiles of the single- and sequential- delivery coatings are illustrated in Fig. 
4.1C and D respectively.  For the in vivo studies, two different coating architectures were used: 
amorphous calcium phosphate with 8 bilayers of PEM (CaP-PEM8), or nanocrystalline calcium 
phosphate with 30 bilayers of PEM (bCaP-PEM30). 
4.2.2 Material Fabrication 
4.2.2.a Preparation of CaP-PEM8 coated Healos® 
Healos® (DePuy Synthes Spine, Raynham, MA) was trimmed to a thickness ~ 1mm, then 
scaffolds were cut out with a 3.5 mm biopsy punch (Integra Miltex, York, PA).  Scaffolds were 
UV-sterilized for 10 min on each side prior to factor adsorption. A 0.5 μg dose of recombinant 
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human bone morphogenic protein 2 (BMP-2, R & D Systems, Minneapolis, MN) was applied to 
the Healos® scaffolds by adding 2 μl of 250 μg/ml stock made in PBS to each scaffold and 
allowing it to adsorbed for 1 h at room temperature. 
 After BMP-2 adsorption each scaffold was placed in a 1.5 ml micro-centrifuge tube and 1 
ml of SBFx5 Solution A (prepared as described in Ch. 2) that is used to precipitate an amorphous 
CaP layer on the scaffold was added to each tube.  Tubes were left open and covered in parafilm 
with 8-10 small holes poked through the parafilm.  Tubes were placed in a 37°C oven.  After ~24 
h tubes were removed from the oven and sonicated (with scaffolds still in reacted SBFx5 
Solution A) for ~ 10 sec to remove loosely bound CaP.  Each scaffold was then placed in a 96-
well plate and rinsed 3x with MilliQ water.  
 Each scaffold was then placed in a 1.5 ml centrifuge tube (EMD Millipore, Billerica, 
MA) with a 0.65 μm filter-membrane. The micro-centrifuge tubes are made up of two 
compartments separated by the membrane; this allows the sample to sit submerged in solution on 
top of the membrane until tubes are centrifuged, which then forces the solution through the 
scaffold and through the membrane, leaving the supernatant separated from the sample. 300 μl of 
1 mg/ml poly-L-Glutamic acid (PLGlut, Sigma, St. Louis, MO) in saline was added to each tube 
and allowed to adsorb to the scaffold for 10 min. Note that the membrane is of sufficiently fine 
porosity that it does not allow the solution to go through it until the centrifugation step therefore 
the scaffold is completely immersed in the solution.  After 10 min, tubes were centrifuged for 
~10 sec at 1000 rpms and the supernatants contained below the membrane were discarded.  Each 
scaffold was then rinsed 3x with saline with centrifugation after each rinse.  Then 300 μl of 1 
mg/ml poly-L-Lysine (PLLys, Sigma, St. Louis, MO) in saline was added to each tube and 
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allowed to adsorb for 10 min, then centrifuged and rinsed 3x with saline.  This procedure was 
repeated until 8 bilayers of PEM were adsorbed (1 bilayer  = PLGlut-PLLys). 
After PEM8 application, recombinant human fibroblast growth factor 2 (FGF-2, R & D 
Systems, Minneapolis, MN) was adsorbed by adding 2 μl of various FGF-2 working stocks 
(prepared in saline) to each scaffold and allowed to bind for 1 h at room temperature.  The 
following doses were tested: 0, 0.25, 5, 100, and 125 ng FGF-2.  After FGF-2 adsorption, the 
scaffolds were rinsed 3x in saline then put in 300 μl DMEM high glucose, pyruvate medium, 
(No. 11995, Gibco BRL, Invitrogen) and stored in a 8-20°C refrigerator until ready for 
implantation.  Prior to implantation the scaffolds were centrifuged for ~ 10 sec at 1000 rpms. 
This entire procedure is illustrated in Fig. 4.2. 
4.2.2.b Preparation of bCaP-PEM30 coated Healos® 
Healos® scaffolds were cut and sterilized as previously described. A 2 μg dose of recombinant 
human bone morphogenic protein 2 (BMP-2, R & D Systems, Minneapolis, MN) was applied to 
the Healos® scaffolds by adding 2 μl of 1 mg/ml stock made in PBS to each scaffold and 
allowing it to adsorbed for 1 h at room temperature. 
For bCaP application, the two-step SBF method described in Ch. 2 was used to produce a 
nanocrystalline bCaP layer rather than just the amorphous layer previously described. During 
BMP-2 adsorption SBF Solution A was prepared as described in Ch. 2.  Scaffolds were added to 
the beaker equipped with a stir bar.  The beaker was covered with saran wrap with 20-30 holes 
punched into it and placed on a stir plate set to match the mixing during Solution A prep (~ 130 
rpms) in a 37°C oven.  After ~24 h the beaker was removed from the oven and sonicated (with 
scaffolds still in reacted Solution A) for ~ 10 sec. Prior to immersion in Solution B, the scaffolds 
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were gradually dehydrated by being passed through a graded series of increasing concentrations 
of ethyl alcohol. 
Solution B was prepared as described in Ch. 2. Scaffolds were added to the beaker 
equipped with a stir bar.  The beaker was covered with saran wrap with 20-30 holes punched into 
it and placed on a stir plate set to match the mixing during Solution B prep (~ 130 rpms) in a 
50°C oven.  After 7 or 24 h, the beaker was removed from the oven and sonicated (with scaffolds 
still in reacted Solution B) for ~ 10 sec. The scaffolds were gradually dehydrated by being 
passed through a graded series of increasing concentrations of ethyl alcohol. 
After bCaP deposition, each scaffold was then placed in a 0.65 μm micro-centrifuge tube 
and 30 bilayers of PLGlut-PLLys were applied as previously described for PEM8. After PEM30 
application, a 5 ng recombinant human fibroblast growth factor 2 (FGF-2, R & D Systems, 
Minneapolis, MN) dose was adsorbed and allowed to bind for 1 h at room temperature. After 
FGF-2 adsorption, the scaffolds were rinsed 3x in saline then put in 300 μl DMEM high glucose, 
pyruvate medium, (No. 11995, Gibco BRL, Invitrogen) and stored in a 8-20°C refrigerator until 
ready for implantation.  Prior to implantation the scaffolds were centrifuged for ~ 10 sec at 1000 
rpms. This entire procedure is illustrated in Fig. 4.3. 
4.2.3 Characterization  
4.2.3.a Scanning Electron Microscopy (SEM) 
The microscopic morphology of the coated scaffolds was characterized using SEM (JSM - 
5900LV, Jeol USA Inc. Peabody, MA). Coated scaffolds were also cut in half, allowing 
examination of the innermost fibers of the Healos® scaffold via SEM.  
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4.2.4 In Vivo Osteogenesis Assays with a Mouse Calvarial Defect Model 
The CD1 female mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used for 
studies at 4-7 months of age. Col 3.6-cyan female reporter mice (with a CD1 background) were 
bred in house and used for studies at 4-7 months of age. Mice in this age range were used 
because they are considered skeletally mature. All animal experimental procedures were 
approved by the Animal Care and Use Committee of the University of Connecticut Health 
Center, (Farmington, CT). 
Mice were anesthetized and placed in a prone position, and the cranium was shaved of 
fur, washed with betadine, and swabbed with alcohol. The periosteum was incised over the 
parietal bone in the frontal plane with a scalpel blade. A 3.5 mm diameter hole was created in the 
center and through one of the two parietal bones using a trephine and avoiding cranial sutures. A 
prepared scaffold was implanted in the calvarial defect, and then the periosteum and 
subcutaneous tissue was closed with sutures, followed by closing sutures of the skin incision. 
The animals were allowed to recover until ambulating and feeding normally. Mice were 
euthanized by asphyxiation with carbon dioxide, and calvaria were harvested after 1, 3, or 4 
weeks post-surgery.  Mice being sacrificed after 1 week were used to evaluate proliferating cells; 
therefore all mice in these groups received peritoneal cavity injections of 3 μg/g EdU (5-ethynyl-
2-deoxyuridine, a nucleoside analog of thymidine) 1 day prior to euthanasia.  New bone 
formation at 3 and 4 weeks was evaluated with x-ray and microCT analysis.  1-6 mice/group 
were used for the calvarial defect studies; specific “n” for each group/study will be indicated in 
results figures. 
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4.2.5 Statistical Analyses 
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey 
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations 
are shown in all figures. 
4.3 Results 
4.3.1 Characterization of CaP, bCaP, and bCaP-PEM coated Healos® 
Amorphous CaP could successfully be deposited on Healos® as evident by SEM (Fig. 4.4), and 
had similar morphology to when amorphous CaP was applied to the sand blasted disks for in 
vitro studies (Fig. 2.3B). bCaP prepared by either 7 h or 24 in Solution B could be deposited on 
Healos®, however, observed porosity decreased with increasing time in Solution B (Fig. 4.5). 
bCaP(7) prepared by 7 h in Solution B, on the outer/surface fibers of the Healos® scaffold had 
the same nanocrystalline morphology (Fig. 4.6C) to bCaP deposited on the sandblasted disks for 
in vitro studies (Fig. 2.3C).  These nanocrystals were still evident on the innermost fibers of the 
Healos® scaffold however they were less densely packed (Fig. 4.6C top vs. bottom panel).  
Uniform deposition of bCaP(7) on outer and inner Healos® fibers was achieved.  After PEM30 
application to Healos-bCaP(7), the nanocrystals of bCaP(7) layer can no longer be observed (Fig. 
4.7).  Similar, uniform morphology was observed for the outer and inner fibers of the Healos® 
scaffold (Fig. 4.7 top vs. bottom panel). 
4.3.2 In Vivo Osteogenesis Assays with a Mouse Calvarial Defect Model 
4.3.2a Determining a Sub-optimal Dose of BMP-2 for CaP-PEM8 Delivery 
0.5 μg BMP-2 delivered from Healos® scaffolds coated with amorphous CaP and 8 bilayers of 
PEM (BMP2-CaP-PEM8) resulted in minimal new bone formation as compared to the BMP-2-
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free control scaffolds after 4-weeks post-surgery (Fig. 4.8).  The new bone formation was only 
evident on the edges of the defect (Fig. 4.8 red circles).  This was considered a desirable result 
because this dose of BMP-2 did not completely heal the defect after 4-weeks implantation; it was 
selected to be used as the control dose of BMP-2 that FGF-2 was used in combination with to 
enhance BMP-2-stimulated in vivo bone formation in future studies. 
4.3.2b Proliferative Effects of the Dual Delivery of FGF-2 and BMP-2 from CaP-PEM8 
The addition of 25 ng FGF-2 to scaffolds coated with BMP2-CaP-PEM8 increased the number of 
EdU positive host cells, therefore proliferating cells, present at the center of the calvarial defect 
1-week after implantation as compared to the BMP-2 only control (Fig. 4.9A, B). The addition of 
125 ng FGF-2 to scaffolds coated with BMP2-CaP-PEM8 significantly increased the number of 
EdU positive host cells, therefore proliferating cells, present at the center of the calvarial defect 
1-week after implantation as compared to the BMP-2 only control and BMP2-CaP-PEM8-FGF2 
(25 ng) (Fig. 4.9C, * p < 0.05, ** p < 0.01). 
4.3.2b Osteogenic Effects of the Dual Delivery of FGF-2 and BMP-2 from CaP-PEM8 
Though it was observed that the 125 ng dose of FGF-2 delivered with 0.5 μg BMP-2 (Healos-
BMP2-CaP-PEM8-FGF2) significantly increased the number of proliferating cells within the 
center of the defect after 1-week implantation, this dose of FGF-2 had an inhibitory effect on 
new bone formation (Fig. 4.10A-D).  After 4-weeks implantation, the FGF-2 and BMP-2 
scaffolds (Healos-BMP2-CaP-PEM8-FGF2) resulted in 0.73 + 0.12 mm3 bone volume, 
compared to the BMP-2 only scaffolds (Healos-BMP2-CaP-PEM8) that resulted in 1.83 + 1.13 
mm3 bone volume (Fig. 4.10E). 
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 These results prompted additional testing of Healos® coated with BMP2-CaP-PEM8-
FGF2 using the 0.5 μg dose of BMP-2, plus 0.25, 5, and 100 ng FGF-2.  After 4-weeks 
implantation the BMP-2 only group resulted in 1.83 + 1.13 mm3 bone volume, and the FGF-2 
doses resulted in 0.17 + 0.17 (0.25 ng), 0.23 + 0.24 (5ng), and 0.35 + 0.24 (100 ng) mm3 bone 
volume. All doses of FGF-2 tested resulted in significant decrease in new bone 
formation/volume compared to the BMP-2 only control (Fig. 4.11, * p < 0.05, ** p < 0.01). 
4.3.2b Osteogenic Effects of the Sequential Delivery of FGF-2 and BMP-2 from bCaP-PEM30 
Healos® coated with nanocrystalline bCaP and 30 bilayers of PEM, and no growth factors, 
(bCaP-PEM30) resulted in minimal to no bone formation after 3-weeks post- calvarial defect 
surgery (0.38 mm3, Fig. 4.12A).  Healos® coated with BMP2-bCaP-PEM30 (BMP-2 = 2 μg) 
resulted in new bone formation only observed around the defect edges (0.89 + 0.32 mm3, Fig. 
4.12B, red circles). Healos® coated with BMP2-bCaP-PEM30-FGF2 (BMP-2 = 2 μg, FGF-2 = 5 
ng) resulted in new bone formation observed around the defect edges and some within the center 
of the defect (1.32 + 0.33 mm3, Fig. 4.12C, red circles). The addition of BMP-2 and FGF-2 
delivered from bCaP-PEM30 resulted in a trend of increasing bone volume as compared to the 
control scaffold with no growth factor and the BMP-2 only scaffold, however these results were 
not statistically significant (Fig. 4.12D).  It should be noted that the BMP-2 only, and BMP-2 and 
FGF-2 groups could not be statistically compared to the growth factor-free control group because 
this group had a n = 1. 
4.4 Discussion 
Growth factors have different effects on natural bone regeneration depending on the 
developmental stage of the healing process they are present during. Specifically, the sequential 
delivery of FGF-2, then BMP-2 has been shown to increase in vitro osteogenesis over co-
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delivery of both factors [88, 90]; therefore, there is a need for new biomaterials to 
biomimetically deliver multiple growth factors in a sequential manner to maximize their 
stimulatory effects.  This chapter focused on the use of the novel, sequential delivery bCaP-PEM 
coating applied to a commercially available bone graft substitute, to deliver FGF-2 and BMP-2 
to enhance in vivo osteogenesis in a mouse calvarial defect model over BMP-2 only delivery. 
 Both BMP-2 and FGF-2 have been successfully delivered individually from calcium 
phosphate/hydroxyapatite materials [195-201], and PEM films and particles [156, 160, 163, 202-
205]. The combination of CaP and PEM without growth factors has been shown to stimulate 
osteogenesis due to CaP’s biomimetic, osteoconductive properties [120, 123, 157, 180].  
Furthermore, the combination of CaP and PEM has also been demonstrated to successfully 
deliver BMP-2 [116, 117].  Due to the synergistic properties of FGF-2 and BMP-2 used in 
combination on osteogenesis, it seemed logical to deliver both growth factors from a calcium 
phosphate/polyelectrolyte biomaterial to stimulate in vivo osteogenesis. 
 Amorphous CaP could be uniformly applied to the fibers of the Healos® scaffold (Fig. 
4.4).  Using the amorphous CaP coating with 8 bilayers of PEM (CaP-PEM8), calvarial defect 
studies were conducted in 4-7 month old female mice to determine first, a suboptimal dose of 
BMP-2, and then to study the proliferative and osteogenic effects of the addition of FGF-2 
delivered with the BMP-2. In all studies the BMP-2 was adsorbed directly to the Healos® 
scaffold, then embedded under CaP-PEM8.  In the groups with FGF-2, FGF-2 was adsorbed as 
the outermost layer of the scaffold coating (Healos-BMP2-CaP-PEM8-FGF2). 
In the first study, 0.5 μg BMP-2 delivered from CaP-PEM8 coated Healos® scaffold 
resulted in minimal bone formation only evident along the edges of the defect after 4-weeks 
implantation (Fig. 4.8, red circles). This was considered a desirable result at the time; the goal of 
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this study was to determine a suboptimal dose of BMP-2 that could not completely heal the 
defect in the 4-week time point because it was hypothesized that the addition of FGF-2 to low 
dose BMP-2 could enhance in vivo osteogenesis; it was first necessary to determine a dose of 
BMP-2 that could be enhanced (because it could not heal the defect alone), and this was 
achieved with the 0.5 μg dose. With continued testing of the BMP-2 only group as the control for 
the FGF-2 dosing experiments, it was determined that the 0.5 μg dose was too suboptimal; with 
or without FGF-2 delivered from the CaP-PEM8 coating, minimal if any bone formation was 
observed after 4-weeks implantation. The lack of observed defect healing is why the dose of 
BMP-2 was increased to 2 μg for continued testing with the bCaP-PEM30 coating, in addition to 
the fact that the bCaP layer is much thicker than the amorphous CaP layer; this dose had 
demonstrated better in vivo efficacy for stimulating bone formation in a similar mouse calvarial 
defect model, [84, 108]. 
The reason FGF-2 was selected to be used in combination with BMP-2 was because it 
was hypothesized that the FGF-2 would stimulate the migration and proliferation of 
osteoprogenitor cells into the calvarial defect, therefore providing more cells within the defect to 
be differentiated and result in better overall healing. The next animal study looked at the 
proliferative effects of adding FGF-2 to the BMP2-CaP-PEM8 coated scaffold after just 1-week 
implantation. The addition of FGF-2 resulted in an observed increase in DAPI+ cells and 
increased EdU+ cells at the center of the defect as compared to the BMP-2 only group (Fig. 4.9). 
This indicated that not only were there more cells present at the center of the defect with 
increasing FGF-2, but these cells were also actively proliferating.  These results confirmed the 
first part of the hypothesis and are supported by the literature [36, 78]. 
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The second part of the hypothesis was that the increase in number of cells present at the 
center of the defect after 1-week would lead to overall increased bone formation after 4-weeks 
implantation.  When looking at total bone volume after 4-weeks implantation, the 0.5 μg BMP-2 
only group again resulted in minimal bone formation, only along the edges of the defect 
(Fig.4.10C, red circles).  The addition of FGF-2 (125 ng) to the BMP-2 resulted in less bone 
formation as evident by microCT (Fig. 4.10D, red circle), and a decrease in quantified bone 
volume, as compared to the BMP-2 only group (Fig. 4.10E).   These results indicate that even 
though the 125 ng FGF-2 was stimulating the proliferation of osteoprogenitors within the defect 
after 1-week, the dose had an overall inhibitory effect on new bone formation after 4-weeks.  It is 
known that too much and/or late stage exposure of FGF-2 can inhibit in vitro and in vivo bone 
formation when delivered with BMP-2 because it can maintain cells in an undifferentiated state 
[90, 93, 194].  This led to the assumption that 125 ng FGF-2 was too high of a dose, and 
prompted additional testing with FGF-2 doses of 0.25, 5, and 100 ng in combination with the 0.5 
μg BMP-2 (Healos-BMP2-CaP-PEM8-FGF2).  All doses of FGF-2 tested significantly inhibited 
bone formation as compared to the BMP-2 only group (Fig. 4.11). 
This led to the hypothesis that delivery of FGF-2 and BMP-2 from the CaP-PEM8 
coating was occurring as co-delivery and not as the intended sequential delivery.  These animal 
studies were conducted concurrently with the in vitro studies reported in Ch. 2 and 3.  To recall, 
the in vitro diffusion studies described in section 2.2.3.b determined that the CaP-PEM8 coating 
significantly improved interlayer diffusion of embedded antimycin A (AntiA) as compared to a 
PEM8 only coating, however, 42% of the cells still accessed at least some of the AntiA within 
the first 24 h resulting in their death (Fig 2.7A).  The conclusion made from this section was “the 
CaP-PEM8 coating would be insufficient for sequential delivery because the embedded ‘Factor 
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2’ can still be accessed immediately”.  In the present animal studies, it is most likely that the 
FGF-2 and BMP-2 are being delivered together from the CaP-PEM8 coating as a co-delivery 
system.  As previously mentioned, it was also decided that the suboptimal dose of BMP-2 
needed to be increased to 2 μg for continued testing. 
Co-delivery of FGF-2 and BMP-2 from PEG hydrogels [84] or colloidal gelatin gels 
[102] can have inhibitory effects on in vivo bone formation when compared to BMP-2 alone.  
Some co-delivery systems such as collagen sponges have even shown that the combination of 
FGF-2 and BMP-2 was not only inhibitory compared to the BMP-2 only group, but was also 
inhibitory compared to the growth factor-free control [100].  Similar results were observed when 
the FGF-2 and BMP-2 were administered as bolus injections in a rat mandible defect; the co-
delivery of factors was significantly worse at inducing bone apposition compared to BMP-2 
alone, and was comparable to the control that was not treated with any growth factors [95]. 
Publications reporting co-delivery of FGF-2 and BMP-2 appear to have conflicting 
results both in vitro and in vivo because dose or dose ratio is not always considered. There are 
publications where the co-delivery of FGF-2 and BMP-2 enhanced in vitro and in vivo 
osteogenesis over single factor delivery and/or spiking [87, 92, 94, 97, 98, 206]; in these studies 
ng quantities of FGF-2 were used and were relatively low compared to the dose of BMP-2 used 
(usually μgs). Both Kuhn et al. and Wang et al. investigated the combined delivery of FGF-2 and 
BMP-2 and provide summaries of the contradictory results [88, 102]. In general, they observed 
that low doses of FGF-2 in combinations with BMP-2 were stimulatory (ng quantities), whereas 
high doses of FGF-2 with BMP-2 were inhibitory (μg quantities). The ratio of FGF-2 to BMP-2 
is also important to consider, where doses of FGF-2 greater than BMP-2 tend to be inhibitory. 
Nakamura et al. hypothesizes that this phenomenon may be the result of high dose fibroblast 
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growth factor stimulating inhibitors of BMP-2 signaling (Smad 6) or stimulating 
osteoclastogenesis that leads to decreased bone formation or bone density [93]. The release 
kinetics from the delivery system may also influence the stimulatory or inhibitory effects of co-
delivery of FGF-2 and BMP-2. As previously mentioned, FGF-2 promotes the mitogenic activity 
of osteoprogenitors, therefore rapid release of FGF-2 early on in bone healing may reduce the 
osteogenic potential of these cells leading to reduced bone formation. 
Contrary to published co-delivery results, sequential delivery of FGF-2 and BMP-2 has 
lead to more consistent stimulatory effects.  This is most likely due to the fact that growth factors 
in general, are very stage-specific during the bone healing process. The sequential delivery of 
first FGF-2, then BMP-2 when spiked into cell cultures results in enhanced in vitro osteogenesis 
over co- or single factor delivery [85, 88, 90, 91]. The challenge arises from developing a truly 
sequential delivery system.  Many materials claim to be “sequential” when in reality they only 
provide the prevention of burst release of the factor they want delivered second; if you check the 
release profiles one will observe that both factors are being released simultaneously, they are just 
releasing at different rates [102, 107, 131, 156, 207, 208].  When release of FGF-2 and BMP-2 
from a material is truly sequential, a stimulatory effect on osteogenesis is usually observed.  Lei 
et al. developed core-shell microspheres where FGF-2 and BMP-2 were encapsulated in either 
the core or the shell.  They demonstrated that the in vitro sequential delivery of first FGF-2 from 
the shell, and then BMP-2 from the core induced osteogenic differentiation of human 
mesenchymal stem cells better than the growth factors delivered in parallel [89].  Sequential 
delivery of BMP-2 first, then FGF-2 was inhibitory, again demonstrating that not only is 
sequential delivery important, but sequential delivery that mimics the natural biological process 
is key to enhancing osteogenesis. 
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In the present study, a stimulatory effect from the delivery of FGF-2 and BMP-2 on in 
vivo osteogenesis was observed when the growth factors were delivered from the bCaP-PEM30 
coating (Fig. 4.12), proven to provide sequential delivery in vitro (Fig. 3.3) and higher doses of 
FGF-2 (5ng) and BMP-2 (2 μg) were used. Though these results were not statistically significant, 
continued studies focused on optimizing the relative dosing of FGF-2 to BMP-2, as well as 
continued work on tuning the in vivo delivery kinetics of the growth factors from the coating 
could lead to the bCaP-PEM coating being ideally suited as a sequential, multifactor delivery 
system capable of being applied to various scaffolds and/or implants for enhanced bone 
regeneration. 
4.5 Conclusions 
Both the novel dual delivery CaP-PEM8 coating, and the novel sequential delivery bCaP-PEM30 
coating could be uniformly applied to the three-dimensional bone graft substitute, Healos®.  Co-
delivery of FGF-2 and BMP-2 from CaP-PEM8 coatings resulted in inhibited in vivo bone 
formation in a calvarial defect model, compared to the BMP-2 only coating. However, sequential 
delivery of FGF-2 then BMP-2, from bCaP-PEM30 coatings resulted in an observed trend of 
increased in vivo bone formation in a calvarial defect model, compared to the BMP-2 only 
coating.  These results suggest the potential for bCaP-PEM30 coating applied to a 3-D implant to 
be used for sequential delivery of multiple growth factors to enhance in vivo bone formation. 
Regardless of the delivery system, these results and others previously published, stress the 
importance of dosing, dose ratio of two different factors, timing, and order of growth factor 
delivery used to enhance in vivo bone regeneration.  Increased doses of BMP-2 with low dose 
FGF-2 should be further investigated. 
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Figure 4.1 Schematic representation of BMP-2 only (A), and BMP-2 and FGF-2 (B) delivery 
from Healos-bCaP-PEM. The theoretical single- (C), and sequential- (D) delivery profiles from 
Healos-bCaP-PEM.  
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Figure 4.2 Schematic representation of the Healos-BMP2-CaP-PEM8-FGF2 procedure made 
with only amorphous calcium phosphate (CaP) with no mixing, and 8 bilayers of PEM. 
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Figure 4.3 Schematic representation of the Healos-BMP2-bCaP-PEM30-FGF2 procedure made 
with biomimetic, nanocrystalline, calcium phosphate (bCaP) with mixing, and 30 bilayers of 
PEM.  
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Figure 4.4 Low magnification SEM images of Healos® (A) and Healos® coated with 
amorphous CaP (B), (scale bar = 50 μm). High magnification SEM image of Healos® coated 
with amorphous CaP (C), (scale bar = 10 μm). 
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Figure 4.5 SEM images of Healos® (A), Healos® coated with nanocrystallline bCaP(7) made 
by 7 h in Solution B (B), and nanocrystalline bCaP(24) made by 24 h in Solution B (C), (scale 
bar = 500 μm).  
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Figure 4.6 Low magnification SEM images of the outer and inner fibers of Healos® (A) and 
Healos® coated with nanocrystalline bCaP(7) (B), (scale bar = 10 μm). High magnification SEM 
image of the outer and inner fibers of Healos® coated with nanocrystalline bCaP(7) (C), (scale 
bar = 1 μm). 
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Figure 4.7 SEM images of the outer (A) and inner fibers (B) of Healos® coated with 
nanocrystalline bCaP(7) and 30 bilayers of PEM. 
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Figure 4.8 4-week post-surgery x-rays (A, B), microCT 3-D reconstructions (C, D), and 
microCT cross-sections (E, F) of calvaria implanted with Healos® coated with CaP-PEM8 (top 
panel) and BMP2-CaP-PEM8 (bottom panel).  BMP-2 dose = 0.5 μg. New bone formation is 
circled in red. 
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Figure 4.9 Schematic representation of where within the defect FGF-2 effects are being 
observed and quantified 1-week post-surgery (A). Fluorescent images of DAPI and EdU stained 
cells showing increase in staining with the addition of 25 and 125 ng FGF-2 as compared to 
BMP-2 alone (B). Quantified results showing 125 ng FGF-2 dose significantly increases number 
of EdU+ cells on day 7 as compared to BMP-2 alone and 25 ng FGF-2 dose (C). (* p < 0.05, ** 
p < 0.01). (Healos® was coated with BMP2-CaP-PEM8 + FGF2). 
ANOVA P value = 0.0029   
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of 
diff. 
Significa
nt? 
Summ
ary 
BMP-2 (0.5ug) vs. BMP-2 (0.5ug) + FGF-2 
(125ng) 
-198.1 -313.1 to -
83.17 
Yes ** 
BMP-2 (0.5ug) + FGF-2 (25ng) vs. BMP-2 (0.5ug) 
+ FGF-2 (125ng) 
-130.3 -245.2 to -
15.30 
Yes * 
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Figure 4.10 4-week post-surgery microCT 3-D reconstructions (A, B), and microCT cross-
sections (C, D), of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (top panel) 
and BMP2-CaP-PEM8-FGF2 (bottom panel).  BMP-2 dose = 0.5 μg, FGF-2 dose = 125 ng. New 
bone formation is circled in red and quantified in (E). 
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Figure 4.11 4-week post-surgery microCT 3-D reconstructions (top panel) and microCT cross-
sections (bottom panel) of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (A), 
and BMP2-CaP-PEM8-FGF2 with an FGF-2 dose = 0.25 ng (B), 5 ng (C), and 100 ng (D).  
BMP-2 dose = 0.5 μg. New bone formation is circled in red and quantified in (E). (* p < 0.05, ** 
p < 0.01). 
ANOVA P value = 0.0027 
Tukey's multiple comparisons test Mean 
Diff. 
95% CI of 
diff. 
Significan
t? 
Summar
y 
0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 0.25 ng 
FGF-2 
1.662 0.6170 to 
2.707 
Yes ** 
0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 5 ng 
FGF-2 
1.602 0.4733 to 
2.731 
Yes ** 
0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 100 ng 
FGF-2 
1.482 0.2753 to 
2.689 
Yes * 
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Figure 4.12 3-week post-surgery microCT 3-D reconstructions (top panel) and microCT cross-
sections (bottom panel) of calvaria implanted with Healos® coated with bCaP(7)-PEM30 (A), 
BMP2-bCaP(7)-PEM8 (B), and BMP2-bCaP(7)-PEM8-FGF2 (C). BMP-2 dose = 2 μg, FGF-2 
dose = 5 ng. New bone formation is circled in red and quantified in (D).  
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Chapter 5 
Suggested Future Directions and Conclusions 
The goal of these studies was to develop a biomaterial capable of sequential delivery of multiple, 
biologically active factors to better stimulate tissue repair that involves a complicated cascade of 
factors in order to regenerate tissue. More specifically, the hope was to develop a coating process 
that could sequentially deliver low dose FGF-2 and BMP-2 with a staggered release of at least 
several days that could be applied to a commercially available bone graft substitute to enhance in 
vivo osteogenesis, with the long-term goal being to overcome clinical complications with high 
dose BMP-2. This work focused on the incorporation of a biomimetic calcium phosphate (bCaP) 
layer into a poly-L-lysine/poly-L-glutamic acid PEM design to prevent interlayer diffusion of 
growth factors resulting in a sequential, multifactor delivery system that could be applied to two-
dimensional (2-D) and three-dimensional (3-D) substrates. The work presented in this 
dissertation proved the hypothesis: If the bCaP barrier layer could prevent diffusion of multiple 
factors within a PEM coating, then sequential delivery of factors could be achieved from a 
bCaP-PEM coated biomaterial. 
During this thesis research a variety of methods were used to modify the MC3T3-E1-
mediated delivery kinetics from PEM coatings and are summarized in Table 5.1. It was shown 
that the unmodified poly-L-Lysine/poly-L-Glutamic acid PEM only coating resulted in interlayer 
diffusion and immediate access to an embedded factor (Fig. 2.7A, 2.9B), proving that a PEM 
only system could not provide sequential delivery of multiple factors. The addition of amorphous 
CaP to PEM prevented some interlayer diffusion of embedded antimycin A (AntiA), however 
significant access to the AntiA had occurred by 24 h (Fig. 2.7-2.8), suggesting it would also be 
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incapable of sequential delivery over the 3+ day time frame that was the goal of this research. 
The addition of nanocrystalline bCaP to PEM (bCaP-PEM30) successfully prevented interlayer 
diffusion of embedded AntiA and provided delayed access to the embedded factor beyond 24 h 
(Fig. 2.9). 
An alternative approach to preventing interlayer diffusion within a PEM coating would 
be to use hydrophobic polyelectrolytes that result in linear growth with the layer-by-layer (LBL) 
application. Hydrophilic poly-L-Lysine (PLLys) and poly-L-Glutamic acid (PLGlut) were 
selected for use because it was known that these polyelectrolytes degraded via cell-mediated 
enzymatic action on the film itself [150], providing localized delivery and a system that does not 
rely on diffusion. Diffusion based systems were avoided because not only are they more difficult 
to control release from, but those system require excessive dosing of growth factor to provide the 
therapeutic concentration to the local tissue.  A cell-mediated delivery system would allow us to 
use low concentrations of growth factor making the biomaterial safer and avoiding the off-target, 
unwanted side effects that are associated with clinical, supraphysiologic dosing [19, 27, 30]. The 
problem with PLLys and PLGlut is that they are hydrophilic, which means that during the LBL 
build up of the film, the polyelectrolytes are constantly rearranging causing an incorporated 
growth factor within the film to also constantly rearrange and resulting is a blended structure 
lacking any ability for sequential delivery.  In the present studies, it was decided to incorporate a 
biomimetic calcium phosphate layer into the PEM system to prevent the interlayer diffusion of 
one of the growth factors and effectively provide sequential delivery.  An alternative that is 
worth further investigation would be to use hydrophobic polyelectrolytes such as hyluronan 
(HA) and/or dextran sulfate (DS) that result in non-diffusing systems [146, 154].  Both of these 
polyelectrolytes result in linear growth. Interlayer diffusion does not occur in these systems, 
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which, as a result, form spatially organized structures wherein factors incorporated at a given 
step are able to interact only with neighboring factors that are in close proximity (two to three 
layers) [209]. The disadvantage to using HA and/or DS is that rather than being cell-mediated, 
their degradation is hydrolytic, meaning release of growth factors depends on the water content 
in the area; this could lead to diffusion of factors away from the target tissue. However, these 
polyelectrolytes can form compartmentalized films to potentially provide sequential delivery 
without the need for covalent cross-linking (which would inactivate the growth factor) or a 
barrier layer. Their use, with low doses of growth factor (minimizing the potential for diffusion), 
is a viable option for future work. 
A combination of a cytotoxic compound (AntiA) and a proliferation compound (FGF-2) 
was found to be the ideal combination to study the multifactor, cell-mediated delivery kinetics of 
the bCaP-PEM coating.  With the cytotoxic AntiA embedded beneath the coating it was easy to 
judge when the cells had significantly attained access to the second factor.  Using this method we 
were able to show that bCaP-PEM coating was capable of local, cell-mediated delivery and did 
not release adsorbed factors through diffusion at the concentrations used in the present study.  
The bCaP-PEM30 coating was able to provide sequential delivery of first FGF-2 and then an 
embedded AntiA, delaying access to the AntiA for up to 3 days when cultured with 
osteoprogenitor cells (Fig. 3.3).  Increasing the number of PEM bilayers (30 to 102) within the 
coating (Fig. 3.4), or changing the chemical composition of the polyelectrolytes (L- to D- 
enantiomers, Fig. 3.5) could not further delay osteoprogenitor access to the embedded AntiA but 
could potentially inhibit/delay delivery of the FGF-2.  .  Increasing (~24 μm) the thickness of the 
bCaP coating from the normal ~6 μm did not change the initial timing of access to the embedded 
AntiA, but did change the delivery of AntiA from burst to sustained delivery over the course of 4 
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days to the osteoprogenitor cells (Fig. 3.8-3.10). Changing the cell type used to evaluate delivery 
kinetics from the coating from osteoprogenitors to macrophages significantly increased access 
time to the embedded factor (Fig. 3.11-3.14).  When the macrophages were seeded at a low 
density (7.9k cells/cm2) the bCaP-PEM30 coating provided 3 days delayed access to the 
embedded factor (Fig. 3.12), similar to the osteoprogenitor cells.  When the macrophages were 
seeded at a high density (30k cells/cm2) the bCaP-PEM30 coating failed to provide any delayed 
access to the embedded factor (Fig. 3.13).  These results highlight the importance of cell type 
and number when evaluating delivery kinetics from a cell-mediated delivery system. 
Considering the variable delivery kinetics of the embedded AntiA from the bCaP-PEM 
coating in vitro, via changing the cell type used in the study, it is critical to better understand the 
mechanism of action various cell types that will interact with the bCaP-PEM coating in vivo, use 
to degrade the coating and access the embedded factor.  Considering the increased in vitro 
delivery kinetics of the embedded AntiA from the bCaP-PEM coating that occurred when 
changing the cell type from pre-osteoblasts to monocyte/macrophages, it is difficult to predict the 
in vivo response from the in vitro studies.  To better predict the in vivo response it is critical to 
better understand the mechanism of degradation of the various cell types that will interact with 
the bCaP-PEM coating in vivo.  Continued in vitro cell assays should be performed using 
different cell types (macrophages, osteoprogenitors, osteoclasts, osteoblasts, etc.) as well as 
different seeding densities or mixtures of the cell types. Evaluation of the bCaP-PEM coating via 
scanning electron microscopy (SEM), after cell culture, should be performed to observe extent of 
coating degradation. 
Both the novel dual delivery CaP-PEM8 coating, and the novel sequential delivery bCaP-
PEM30 coating could be uniformly applied to the three-dimensional bone graft substitute, 
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Healos® (Fig. 4.4-4.7).  Co-delivery of FGF-2 (0.25, 5, 100, 125 ng) and BMP-2 (0.5 μg) from 
CaP-PEM8 coatings resulted in inhibited in vivo bone formation in a calvarial defect model, 
compared to the BMP-2 only coating (Fig. 4.10-4.11).  Considering these results, it was 
determined that the 0.5 μg BMP-2 dose was too low. However, sequential delivery of FGF-2 (5 
ng) then BMP-2 (2 μg), from bCaP-PEM30 coatings resulted in an observed trend of increased in 
vivo bone formation in a calvarial defect model, compared to the BMP-2 only coating (Fig. 
4.12).  Further studies with a larger number of animals may increase this effect.  Increasing the 
dose of BMP-2 is also necessary in order to see a benefit from combined FGF-2 delivery. These 
results and others previously published, stress the importance of dosing, ratio of doses, timing, 
and order of growth factor delivery used to enhance in vivo bone regeneration. Further studies 
need to be conducted to optimize the dosing of FGF-2 and BMP-2 to lead to robust, new bone 
formation in vivo that cannot be achieved by BMP-2 alone. 
In summary, the work presented in this dissertation resulted in the development of novel 
biomimetic calcium phosphate/polyelectrolyte coating capable of cell-mediated, sequential, 
multifactor delivery, providing three-day delayed access of an embedded factor to 
osteoprogenitor and macrophage cells. This technology has the versatility to be applied to 2-D or 
3-D substrates and can be utilized in multiple research applications where a sequential delivery 
profile activated by cell degradation of matrix is desired. The results suggest the biomimetic 
calcium phosphate/polyelectrolyte coating applied to a 3-D implant could be an ideal system for 
sequential delivery of multiple growth factors to enhance in vivo bone formation.  
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Table 5.1 Summary of cellular access timing to embedded AntiA (213 μg/disk) when cultured 
on the various coatings reported in this thesis. (FGF-2 Dose = 150 ng). 
AntiA Embedded 
Beneath 
Cell Type Seeding Density 
(cells/cm2) 
Access Time 
PEM8 MC3T3-E1 10k < 24 h 
CaP-PEM8 MC3T3-E1 10k < 24 h 
CaP-PEM30 MC3T3-E1 10k < 24 h 
PEM30 MC3T3-E1 40k < 24 h 
bCaP-PEM30 MC3T3-E1 40k 3 days 
bCaP-PEM30-FGF2 MC3T3-E1 40k 3 days, burst delivery 
bCaP-PEM102-FGF2 MC3T3-E1 40k 3 days 
bCaP-PEMD30-FGF2 MC3T3-E1 40k 3 days 
bCaP(7)-PEM30-FGF2 MC3T3-E1 40k 3 days 
bCaP(48)-PEM30-FGF2 MC3T3-E1 40k 3 days/sustained delivery 
bCaP-PEM30-FGF2 RAW 264.7 7.9k 3 days 
bCaP-PEM30-FGF2 RAW 264.7 30k < 4 h 
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